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Metabolic syndrome (MetS) encompasses metabolic abnormalities that substantially 
increase risk for chronic illnesses. MetS and stress are closely related; the pathophysiology of 
MetS involves dysregulated stress response in both the physiological and psychological domains. 
In an effort to further clarify the relationship between metabolic abnormalities and autonomic 
dysregulation, we used ambulatory impedance cardiography (ICG) to examine indicators of 
cardiac autonomic control (CAC) in a sample of 50 adult primary care patients with and without 
MetS. Indices of sympathetic and parasympathetic influences on cardiovascular functioning were 
assessed in the context of psychological stressors and compared across experimental groups and 
examined in relation to self-reported health measures. Primary results suggest that while our 
experimental groups did not differ significantly on baseline measures, patterns of responses to 
experimentally induced stressors were largely consistent with our predictions, and demonstrate 
that individuals with MetS responded to stress cues with more maladaptive CAC scores. 
Moreover, in line with previous work, we found that elements of CAC in our sample were 
predictive of both cardiovascular disease and self-reported environmental quality of life. Overall, 
our results suggest that maladaptive physiological manifestations of the stress response are 
evident among individuals with MetS and may also be related to long-term health outcomes. The 
present study carries implications for both evaluation and assessment as well as treatment 
delivery and monitoring. In addition, the ambulatory nature of data collection demonstrated here 
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CHAPTER ONE: INTRODUCTION AND LITERATURE REVIEW 
 
 Metabolic syndrome (MetS; also labeled “insulin resistance syndrome,” DeFronzo, & 
Ferrannini, 1991) represents a constellation of metabolic abnormalities that substantially increase 
risk for cardiovascular disease (CVD) and diabetes mellitus, type 2 (DM2). MetS is related 
closely to lifestyle factors (Grundy et al., 2006; Tentolouris, Argyrakopoulou, & Katsilambros, 
2008), but stress also contributes to the development and maintenance of MetS (Blumenthal et 
al., 2012; Hjemdahl, 2002; Rosmond, 2005; Schwartz et al., 2003; Vitaliano et al., 2002). 
Moreover, embodied psychological phenomena during periods of stress are important 
determinants of illness (Adler, 2002; Blascovich & Mendez, 2000; Burke, Davis, Otte, & Mohr, 
2005; Cacioppo & Tassinary, 1990; Carroll et al., 2012; Celano et al., 2013; Lambert, 
Straznicky, Lambert, Dixon, & Schlaich, 2010; Prkachin, Williams-Avery, Zwaal, & Mills, 
1999). In MetS, one unresolved issue involves the extent to which these determinants are 
pathophysiological, and how these determinants relate to disease progression. The purpose of 
this investigation is to examine cardiovascular responses to stress among individuals with MetS 
and to explore the impact of these responses on health behavior and treatment adherence. 
Metabolic Syndrome 
Clinical Features 
MetS is not a new condition (Kylin, 1923), and a growing body of research has 
dramatically improved our understanding of its role in chronic illness. In an effort to reconcile 
discrepant diagnostic criteria, The American Heart Association and the National Heart, Lung, 
and Blood Institute (NHLBI; Grundy et al., 2006), issued a joint report clarifying the five clinical 
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features of MetS. They include (1) elevated waist circumference, (2) elevated triglycerides (3) 
reduced high-density lipoprotein (HDL) cholesterol, (4) elevated blood pressure (BP) and (5) 
elevated fasting blood glucose (fBG). Table 1 outlines MetS criteria as defined by the NHLBI.  
Table 1. Metabolic Risk Measurement and Diagnostic Criteria for Metabolic Syndrome 
Measure Clinical Threshold/Cutoff Normal Range 
1. Waist circumference ≥ 102 cm in men 
≥ 88 cm in women 
< 102 cm in men 
< 88 cm in women 
2. Triglycerides ≥ 150 mg/dL  
– or – 
On drug treatment for elevated 
triglycerides 
< 150 mg/dL 
3. High-density lipoprotein < 40 mg/dL in men 
< 50 mg/dL in women 
– or – 
On drug treatment for reduced HDL 
40-49 mg/dL in men 
50-59 mg/dL in women 
– or – 
60 mg/dL and above 
4. Blood pressure ≥ 130 mm Hg systolic 
– or – 
≥ 85 mm Hg diastolic 
– or – 
On antihypertensive drug treatment in 
a patient with a history of 
hypertension 
≤ 120 mm Hg systolic 
 
≤ 80 mm Hg diastolic 
5. Fasting glucose ≥ 100 mg/dL 
– or – 
On drug treatment for elevated 
glucose 
70-99 mg/dL 
Note: Adapted from Grundy et al. (2006) Reprinted with permission, Circulation.2005;112:2735-
2752, ©2005, American Heart Association, Inc.; Additional sources: The Mayo Clinic,  
 
These risk factors are all interrelated, and while visceral adiposity (Carr et al., 1994) and 
insulin resistance (Ferrannini, Haffner & Mitchell, 1991) are thought to underlie metabolic 
abnormalities, there is most likely not a single cause for the syndrome (Grundy et al., 2006; 
Canale et al., 2013). 
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Developmental Features 
Onset of MetS is difficult to determine because the component features develop 
gradually, and can wax and wane in the early stages of the syndrome. Genetic factors predispose 
individuals to some degree of metabolic dysregulation. There is evidence that genetically 
moderated hormonal hypersensitivity along the hypothalamic-pituitary-adrenal (HPA) axis is 
important in the maintenance of MetS (Rosmond, 2005). It appears also that metabolic and 
biochemical processes differ as a function of race (Anderson, McNeilly, & Myers 1993; Haffner 
et al., 1996), corroborating genetic contributions. Such biological and genetic influences become 
amplified by lifestyle factors including physical inactivity and poor diet. 
Lifestyle factors increase the propensity for obesity and insulin resistance, the two 
underlying risk factors for MetS. Park et al. (2003) studied lifestyle and physiological variables 
that contribute to MetS in a sample of 12,363 individuals drawn from the Third National Health 
And Nutrition Examination Survey (NHANES III). Findings indicate that men (who are at an 
increased risk for metabolic syndrome, Katano et al., 2010), were significantly more likely to 
develop MetS if they were inactive and consumed high quantities of carbohydrates. Other 
lifestyle variables (e.g., smoking, alcohol use) are linked to increased odds of developing MetS 
(Katano et al., 2010; Park et al., 2003; Zhu, St. Onge, Heshka, & Heymsfield, 2004). Therefore, 
treatment for MetS first and foremost incorporates behavior change and lifestyle modification. 
Stress and Metabolic Risk 
Stress increases metabolic risk, and has been associated with MetS and other chronic 
conditions on theoretical and empirical grounds (Blumenthal et al., 1995; Brunner et al., 2002; 
Canale et al., 2013; Koivistoinen et al., 2010; Novak et al., 2013; Rosmond, 2005; Tentolouris et 
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al., 2008; Thayer, Yamamoto, & Brosschot, 2010). Several trends in the literature support this 
conclusion. 
First, prevalence rates of MetS are higher among individuals facing chronic psychosocial 
stressors compared to those who are not. It has been estimated that between 6% and 23% of the 
variance in MetS can be attributable to chronic stress (Vitaliano et al. 2002). Chandola, Brunner, 
and Marmot (2006) analyzed data from over ten thousand individuals in the Whitehall II study 
and found that the accumulation of chronic work stress over a 14-year period increased odds for 
MetS development by 125 percent.  
Second, physiological mechanisms underlying insulin resistance and obesity have been 
linked to autonomic activation (Canale et al., 2013; Flaa et al., 2008; Hjemdahl, 2002; Lambert 
et al., 2010). Masuo, Mikami, Ogihara, and Tuck (1997) concluded that heightened physiological 
activation was predictive of obesity and hypertension over a 10-year period among both 
hypertensive and normotensive adults. This association has been argued on conceptual grounds 
as well. Julius, Valentini, and Palatini (2000) proposed that physiological activation in response 
to stress impacts obesity directly through altering beta-adrenergic sensitivity, and indirectly 
through increasing insulin resistance. 
Finally, several studies have concluded that autonomic dysregulation precedes 
development of MetS (DeCouck, Mravec, & Gidrron, 2012; Koivistoinen et al., 2010; Masi, 
Hawkley, Rickett, & Cacioppo, 2007; Tentolouris et al., 2008, Thayer et al., 2010). Notably, 
Chang et al. (2010) examined a sample of pre-disease participants at risk for MetS and found that 
those with more risk factors evidenced maladaptive physiological stress patterns in response to 
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standardized stressors. In addition, Licht and colleagues (2013) found that in a sample of 1933 
adults, measures of autonomic dysregulation were predictive of MetS risk factors two years later.  
A core theme in the investigations described above is cardiovascular reactivity (CVR). 
The physiology of CVR and the anatomy of the cardiovascular system (CVS) are central 
indicators of the body’s typical stress response and can help clarify why stress becomes 
pathogenic for these patients (Curtis & O’Keefe, 2002; Lambert et al., 2010; Soares-Miranda et 
al., 2012; Tentolouris et al., 2008). 
The Cardiovascular System  
 The heart, arteries, veins, and capillaries constitute the CVS – a system highly responsive 
to biological and environmental changes. The CVS is under the control of both intrinsic and 
extrinsic mechanisms (Berntson, Quigley, & Lozano, 2007; Andreassi, 2007).  
 
 
Figure 1. Anatomy and Physiology of Electrical Elements Controlling the Cardiac Cycle. 
Adapted from Berntson et al. (2007). Note: Dotted lines denote direction of depolarization; RA = 




 Electrochemical activity within the myocardium controls the cardiac cycle. The cardiac 
cycle refers to the sequence of events in the heart that occur from one beat to another. The cycle 
consists of two epochs: systole, during which myocardium contracts and pumps blood, and 
diastole, during which the myocardium relaxes and the chambers fill with blood (Berntson et al., 
2007; Andreassi, 2007).  
Systole and diastole occur through depolarization of electrically active muscle fibers 
within the heart beginning in the sinoatrial (SA) node located in the right atrium (see Figure 1). 
Depolarization travels downward to the atrioventricular (AV) node, initiating contraction of the 
atria, and completely filling the ventricles. The electrical impulse propagates down the right and 
left bundle branches terminating in the Purkinje network. This final sequence of depolarization 
causes ventricular contraction, which ejects blood toward the periphery and lungs. Polarization 
occurs during the diastolic epoch as negative pressure builds in the ventricles, causing an inflow 
of blood to the atria (Andreassi, 2007).  
Electrocardiogram (ECG) is a common method used to assess cardiac function 
(Andreassi, 2007; Berntson et al., 2007). ECG records electrical fluctuations on the surface of the 
skin caused by myocardial depolarization. This electrical fluctuation translates to a specific 
waveform, characterized by upward and downward deflections over time. In the ECG signal, the 
QRS complex denotes depolarization down the AV bundle and corresponds to ventricular 
contraction. This signal is used to derive measures of cardiac activity including heart rate (HR) 
and heart rate variability (HRV). Figure 2 depicts the standard ECG waveform (including the 




Figure 2. Comparison of Physiological, Electrical, and Phonographic Features of the Cardiac 
Cycle Over Time. (Adapted from Berntson et al., 2007). 
 
Impedance cardiography (ICG) is a non-invasive procedure that permits measurement of 
physiological features in the heart. ICG records the voltage differential between opposing pairs 
of dorsal and ventral sensors by applying a high-frequency, constant-current electrical flow to the 
torso. Contrary to ECG’s measurement of electrical activity, ICG facilitates computation of 
systolic (pre-ejection period) and volumetric indices (e.g., stroke volume) of cardiac functioning. 
There is some evidence that hemodynamics in individuals with MetS may be compromised (i.e., 
irregular; Wahba & Mak, 2007) due to the significant impact of metabolic dysregulation on the 
cardiovascular system. However, in a thorough investigation involving approximate entropy 

























































(ApEn) analysis, Guerra et al. (2011) did not detect differences in systolic or volumetric ICG 
indices between MetS patients and healthy controls. 
The vasculature is also under control of intrinsic mechanisms that regulate blood flow 
and pressure. Blood flow (F) within a vessel is a function of the pressure differential along a 
gradient (i.e., between point 1 and point 2; P1-P2) and the inverse of the resistance (R) to that 
flow, such that F = (P1-P2)/R. That is, along a constant pressure gradient, flow decreases as 
resistance increases. Whereas resistance depends on persistent factors such as blood viscosity 
and local intravascular conditions (e.g., atherosclerosis), blood pressure (BP) depends on 
transient factors such as cardiac output (CO) and vasoconstriction/dilation (Andreassi, 2007). 
Therefore, regulation of BP is the most efficient means of manipulating momentary blood flow 
in the periphery.  
Vascular functioning is more challenging to quantify at a given point because blood 
pressure fluctuates greatly throughout the circulatory system. For instance, BP in the aorta and 
large arteries is markedly greater than in the venae cavae and large veins, due to their location 
within the circulatory system and their ability to distend (Berntson et al., 2007). Oscillometric 
blood pressure monitoring (OBP) is a measurement approach that enables peripheral vasculature 
to be monitored remotely (Berntson et al., 2007). OBP can provide estimates of systolic, diastolic 
and mean arterial pressure (MAP; Berntson et al., 2007; Babbs, 2012).  
Extrinsic Control 
Extrinsic control of the CVS occurs through interdependent mechanisms in the central 
nervous system (CNS), autonomic nervous system (ANS), and HPA axis. The majority of CNS 
control is automatic and is housed in primitive brain stem structures including the medulla and 
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cerebellum (Andreassi, 2007; Berntson et al., 2007). Additionally, baroreceptors in the carotid 
sinus provide reflexive feedback to these brain structures, increasing HR when blood pressure 
decreases. These lower-level mechanisms give rise to higher-level central and autonomic control 
(Berntson & Cacioppo, 2007; Berntson et al., 2007).  
Synergistic coactivation of the HPA axis and the ANS provides much of the extrinsic 
control for the CVS. Hormonal substrates initiate activity along the two branches of the ANS, 
providing electrochemical impulses for local alterations in muscle and tissue (Andreassi, 2007; 
Berntson & Cacioppo, 2007; Berntson et al., 2007). The sympathetic nervous system (SNS) 
maximizes blood flow to large muscle groups, constricts peripheral vasculature, and increases 
cardiac output, thereby energizing the body. The parasympathetic nervous system (PNS) opens 
channels of blood flow, dilates peripheral vasculature, and slows heart rate (HR) and respiration, 
thereby conserving energy.  
Hormonal facilitation in the CVS is important because it provides impetus for SNS and 
PNS projections to alter heart rate (chronotropic effects; primarily related to PNS activation), 
muscle contractility (inotropic effects; primarily related to SNS activation) and peripheral 
vasoconstriction (also sympathetically moderated). The speed of SNS and PNS effects are 
considerably different (Berntson et al., 1997; Berntson et al., 2007). PNS activation can produce 
significant chronotropic effects almost immediately, whereas SNS activation has a longer, more 
cumulative impact on cardiovascular function (Andreassi, 2007, Somsen et al., 2004). 
Accordingly, the SNS and PNS play a central role in determining how the CVS adapts (or fails to 
adapt) to demands placed upon it. This process is known as cardiac autonomic control (CAC). 
Empirical evidence suggests that dysregulated CAC within these branches may place an 
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individual at risk for health complications (Chang et al., 2010; Hemmingway et al., 2005; 
Lambert et al., 2010; Masuo et al., 1997). One explanation for this relationship lies in the 
physiological stress response. 
 Physiological Stress Response  
Selye (1956) described stress as a physical state that manifests via stereotypic responses 
in the face of a particular demand on the body. This definition highlights two important elements 
of the stress construct. First, stress is not a discrete external condition, but rather an internal state 
that arises in context of external demands (i.e., stressors). Second, the body’s response is 
stereotypic; it has a predictable and consistent temporal sequence when triggered.  
Biological Self-Regulation 
In the presence of internal or external demands, activity across body systems fluctuates to 
maintain homeostasis (i.e., equilibrium around a particular set point). This process was referred 
to initially as homeostatic regulation (Berntson & Cacioppo, 2007). Cannon (1939) formulated a 
number of initial concepts related to autonomic processes in homeostatic regulation that have 
had a lasting impact on the understanding of physiological stress response. Namely, that 
regulatory effects of the SNS and PNS are balanced (Wenger, 1941), reflexive (Randall, 
Wurster, Randal, & Xi-Moy, 1996), and characterized by reciprocal central control (Berntson & 
Cacioppo, 2007). Seyle (1973) refined the conceptualization of this process by suggesting that 
the regulatory level is necessarily flexible to compensate for changing demands. The term 
allostasis or allodynamic regulation (Sterling & Eyer, 1988) encompasses the notion that 
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stability must be achieved through change and reflects the finding that autonomic regulation of 
the body is subject to constantly changing internal and external criteria (Dworkin, 1993). 
Autonomic Space 
Consistent with broad models of biological self-regulation, early conceptualizations of 
autonomic regulation also held that SNS and PNS activity was reciprocal, existing along a 
continuum from sympathetic to parasympathetic dominance. Findings pertaining to this 
continuum support the notion that SNS activation occurred with PNS inhibition, and vice versa 
(Malliani, 1999).  
However, other empirical investigations revealed differences in the specific modes of 
ANS activation during times of stress (Iwata & LeDoux, 1988; Koizumi & Kollai, 1981; Quigley 
& Berntson, 1990). These findings suggested separation of SNS and PNS activity that appeared 
to override tendencies toward reciprocity. In turn, Berntson and colleagues (Berntson, Cacciopo 
& Quigley, 1991; 1993a; Berntson, Cacciopo, Quigley & Fabro, 1994) formulated the doctrine 
of autonomic space, which accounts for fluidity in autonomic activation. This model holds that 
ANS activity is best understood within orthogonal two-dimensional space enabling SNS and 
PNS activation to be reciprocal, coactive, or uncoupled (see Table 2).  
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In support of this model, Bernston, Norman, Lawkley, and Cacioppo (2008) provide 
evidence that cardiovascular changes related to autonomic control reflect multiple configurations 
of SNS and PNS activity. The research team collected numerous CVS measures from a sample 
of 229 adult participants in the community during a three-year epoch of the Chicago Health, 
Aging, and Social Relations Study. The team used data from ECG and ICG recordings to derive 
measures of CAC (see Figure 3), which they labeled cardiac autonomic balance (CAB; based on 





Figure 3. Relationship Between CAB and CAR within the Doctrine of Autonomic Space. 
 
The team compared these and other markers of SNS and PNS activity (e.g., HR and 
HRV) to various subjective and objective health outcomes including DM2, myocardial infarction 
(MI), and quality of life. The results further indicated that those with low CAR scores were more 
likely to have a history of MI, where as those with low CAB scores were more likely to have a 
history of DM2. Moreover, the authors concluded that CAR (but not CAB) was predictive of 
global health, physical well-being, and pain as measured through self-report after controlling for 
demographic variables. These findings not only support the notion that SNS and PNS activation 
may occur in a variety of configurations, but also indicate that each carries implications for 
physical health. The findings are also consistent with literature suggesting dysregulated 
autonomic activity is associated with chronic illness. 
Licht et al. (2010) developed a separate study to demonstrate that CAC has unique 
etiological implications for MetS. Working from the doctrine of autonomic space, the authors 
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utilized longitudinal data to examine CAC and HPA activity among a cohort of participants in 
the Netherlands Study of Depression and Anxiety (NESDA) over a three-year period. The 
authors monitored CAB, CAR, and salivary cortisol levels among 1,883 adults who presented 
with varying degrees of metabolic risk, ranging from none (0 risk factors) to severe (all 5 
factors). The authors then compared response patterns across participants to determine the extent 
to which autonomic (as opposed to hormonal) activity relates to metabolic abnormalities. Results 
indicated not only that individuals with MetS show lower CAB and CAR, but also that these 
variables were linearly related to the number of metabolic abnormalities. The authors determined 
that hormonal measures did not have metabolic implications, pointing to the specific effect of 
ANS activity in the development of MetS. These findings lend support to the notion that across 
individuals, patterns of CAC are related to distinct physical outcomes. 
The doctrine of autonomic space offers an effective description of CAC, but does not 
clearly explain the ways in which this process can lead to MetS. Furthermore, these studies are 
limited by a failure to monitor psychosocial features of the stress response. This limitation is 
particularly important because the psychological stress response may help explain the 
relationship between CAC and MetS. 
Psychological Stress Response 
Psychological variables are known to play a crucial role guiding patterns in allodynamic 
regulation during times of stress (Berntson & Cacioppo, 1999; Curtis & O’Keefe, 2002; 
Jorgensen & Kolodziej, 2007; Lambert et al., 2010). Current theory suggests the extent and 
intensity of the stress response is mediated by the psychological response to the stressor. This 
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response is commonly labeled appraisal (Lazarus, 1993; Lazarus & Folkman, 1984; Schwartz et 
al., 2003).  
Appraisal is built upon two complementary processes: primary (or demand) appraisal and 
secondary (or resource) appraisal (Blascovich & Mendes, 2000; Blascovich & Tomaka, 1996). 
Primary appraisal refers to the judgment of situational danger and/or required effort. Secondary 
appraisal refers to the judgment of personal skills or knowledge relevant to performance in light 
of the situation (Blascovich & Mendes, 2000). The resolution of the primary-secondary appraisal 
process establishes a particular motivational state that leads to cognitive and behavioral 
tendencies intended to cope with the stressor.
1
 This motivational state is highly relevant 
physiologically; it ensures the body responds to the external demand in a manner consistent with 
primary and secondary appraisals.  
The Biopsychosocial Model of Challenge and Threat 
Blascovich and colleagues’ biopsychosocial model of challenge and threat (Blascovich, 
2008; Blascovich & Mendez, 2000; Blascovich & Tomaka, 1996) outlines how differences in 
primary and secondary appraisals underlie specific motivational states and describes how these 
states manifest in the body. The model stipulates that in the context of motivated performance 
                                                 
1
 A fundamental distinction with regard to coping strategies involves whether the strategy moves 
the individual toward (approach) or away (avoidance) from a particular target, object, or goal 
(Elliot & Fryer, 2008). It has been suggested that approach-avoidance dichotomy can be mapped 
on to the challenge-threat model; however, one particular motivational state does not universally 
precede one particular behavioral coping strategy. The concordance between these two concepts 
is complicated further by mediating and moderating variables including gender, dispositional 
traits, and sociocultural norms. A more accurate parallel concept may be active vs. passive 
coping, which relates to the individual’s perceived resources as opposed to objects, targets, or 
goals.  
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situations (i.e., those that require instrumental cognitive or behavioral performance), an 
interaction between affective and cognitive evaluations during the appraisal process determines 





Figure 4. Blascovich & Colleagues’ (a) Biopsychosocial Model of Challenge and Threat and (b) 
Theoretical Cardiovascular Patterns Associated with Each Motivational State. 
Note: Adapted from Blascovich & Mendes (2000); PEP = Pre-ejection Period (cardiac 
contractility); TPR = Total Peripheral Resistance (vascular response) 
 
Challenge states occur when the available resources are judged to be equivalent to or 
outweigh the perceived demand. Threat states occur when situational demands are judged to be 
greater than the available resources. The authors theorize that certain variables moderate 
processes of demand and resource appraisal including uncertainty, physical and psychological 
danger, skills, knowledge and support; they also propose that these states tend to carry hedonic 
valance, noting threat is more likely to elicit negative affect. 
The authors submit that challenge and threat motivational states are associated with 
















































as previous work by Obrist (1981) and Dienstbier (1989). The model suggests that challenge 
states are marked by decreases in total peripheral resistance in conjunction with increased 
cardiac output (cardiac-somatic coupling), producing little change in blood pressure. Conversely, 
threat states are associated with minimal increases in total peripheral resistance in conjunction 
with increased cardiac output (cardiac-somatic uncoupling), which has the effect of increasing 
blood pressure (see Figure 4b). This theoretical model gained support through experimental 
studies that confirm expected cardiovascular patterns among individuals in challenge and threat 
motivational states (Tomaka, Kibler, Blascovich, & Ernst, 1997; Blascovich, Seery, Mugridge, 
Norris, & Weisbuch, 2004).  
Challenge, Threat, and Illness 
Blascovich (2008) suggests that challenge states tend to be adaptive (synchronous cardiac 
activation and vasodilation that facilitate effective performance), while threat states tend to be 
maladaptive (asynchronous cardiac activation and vasoconstriction that inhibit effective 
performance). The initiation of threat states leads to cardiovascular strain in non-metabolically 
demanding situations. Therefore, the direct relationship between challenge/threat states and 
health is one that can be defined and tested.  
Blascovich and Katin (1993) note that vascular contractility in conjunction with increased 
cardiac output (i.e., threat state) precipitates blood turbulence within coronary arteries and acute 
hypertension. This process can produce lesions in the endothelial lining of these arteries 
increasing the likelihood of scarring and arteriosclerosis. In addition, Manuck, Kamarck, 
Kasprowicz, and Waldstein (1993) concluded that repeated elevations in blood pressure 
consistent with threat states impede intrinsic hemoregulatory mechanisms, potentially 
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precipitating clinical hypertension. Indeed, persistent activation of this pattern of appraisal is 
associated with an increase in allostatic load (i.e., a systemic failure of regulatory mechanisms 
brought on by chronic stress), which leads to heightened baseline activation in body systems 
under hormonal and autonomic control (McEwen & Stellar, 1993). 
Challenge and threat states can impact physical health in other ways. An intriguing 
extension of this model yet to be tested suggests that particular patterns of PNS and SNS 
activation along with the cardiovascular profiles of challenge and threat states create an indirect 
line of influence on MetS by attenuating health behavior and treatment adherence. Treatment 
non-adherence is related strongly to increased disease progression, particularly in CVD and DM2 
(Asche, LaFleur & Conner, 2011; Bodenheimer, Lorig, Holman & Grumbach, 2002; Dunbar-
Jacob & Mortimer-Stephens 2001; Gonzalez et al., 2008; Lerman, 2005). It is possible that 
perceiving insufficient resources in motivated performance situations both (1) increases negative 
affect (e.g., worry, fear, depression; Blascovich & Mendes, 2000) and (2) inhibits tendencies 
toward health behavior and/or adhering to treatment recommendations, thereby minimizing 
illness-based stress. Indeed, theories of treatment adherence such as the Health Compliance 
Model-II (HCM-II; Heiby & Frank, 2003) suggest motivational state and emotional experience 
are chief determinants of treatment adherence and health behavior (Heiby & Lukens, 2006).  
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The Proposed Investigation: Aims and Hypotheses 
Based on current literature and unresolved questions, we have developed four study aims 
and corresponding hypotheses. 
Table 3. Study Aims and Hypotheses. 
Aim 
 
1 Validate the relationship between CAC and MetS 
   
 
H1 Consistent with findings from Berntson et al. (2008), both CAB and CAR will 
predict concurrent diagnosis of DM2 and CVD. CAC will be positively related 
to self-reported well-being and negatively related to depression and anxiety. 
 
H2 Patients with metabolic syndrome will evidence lower baseline CAB & CAR 
scores.  
2 
Examine the patterns of CAC among patients with MetS during a standardized 
stressor. 
   
 
H3 Patients with metabolic syndrome will evidence lower CAB & CAR scores 
during standardized stressors. 
3 
Examine the patterns of CAC among individuals with MetS during a health and 
wellness interview. 
   
 
H4 Patients with metabolic syndrome will evidence lower CAB & CAR scores 
during the health and wellness interview. 
 
H5 During the experimental tasks, responding with a cardiovascular “threat” 
configuration will be associated with MetS. 
4 
Examine the influence of cardiac autonomic control on health behaviors & 
treatment adherence among individuals with MetS. 
   
 
H6 Low CAB & CAR scores will be associated with increased BMI, decreased 
physical activity, increased smoking behavior, increased drinking, and 
decreased self-reported medication adherence. 
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CHAPTER TWO: METHODOLOGY 
Participants 
Participants were 51 primary care patients at the University of Central Florida Health 
Clinic (UCFH) who were identified as study candidates by having any number of metabolic 
abnormalities consistent with NHLBI guidelines. Within this full sample, 25 individuals met 
diagnostic criteria for MetS as confirmed by their referring physician, and 26 individuals were 
identified as “healthy controls” (HC; presented with two or fewer metabolic abnormalities). One 
individual in the HC group was removed form the initial sample due to failure of the ambulatory 
monitoring device. The final sample (N=50) was predominantly female (68%) with a mean age 
of 56.32 years (SD=16.74). The majority of the final sample identified as Caucasian (64%) with 
a smaller proportion identifying as Latino/a (16%), Black/African American (12%) and Asian 
(8%). Table 4 (see Results section, below) provides more specific information about the final 
sample, including demographic and medical characteristics of each of the experimental groups as 
well as analysis of group differences along these characteristics. 
Measures 
Metabolic Syndrome 
The NHLBI guidelines (Grundy et al., 2006) stipulate that three of five risk factors must 
be present for diagnosis of MetS (see Table 1). These criteria have been adjusted from previous 
guidelines to reconcile differences in interpretive ranges and the complication of frequently 
prescribed medications targeting metabolic abnormalities. Assessment of these abnormalities 
were be conducted through measurement of waist circumference in the case of risk factor 1, and 
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using current medical records, laboratory tests, and vital signs in the case of factors 2-5. 
Following diagnostic guidelines, waist circumference was measured using a measuring tape 
placed around the abdomen on a horizontal plane (parallel to the floor) at the level of the iliac 
crest. The research team consulted medical records, laboratory tests, vital signs, and medication 
prescription records to confirm the existence of metabolic risk factors. 
Cardiac Autonomic Control 
Accurate and reliable measurement of CAC necessitates an ensemble of measures that 
include ECG, ICG and OBP. We utilized ambulatory measurement for each of these signals. 
Participants were seated for all data collection procedures. 
ECG and ICG 
ECG and ICG were recorded simultaneously using a series of adhesive sensors affixed to 
the participant’s skin. ECG was recorded using two Ag/AgCl spot electrodes in standard Lead-II 
configuration. The typical reference, or “ground,” electrode in ECG monitoring was assigned to 
one of the ICG electrodes. ICG was recorded using four Ag/AgCl adhesive spot electrodes 
placed in corresponding dorsal and ventral sites (see Figure 5). These sensors were connected via 
touchproof snap leads to an ambulatory monitoring device (MindWare Mobile) provided by 
MindWare Technologies (Gahannah, OH). Offline, data were subjected to a band pass and notch 
filters to remove movement and electrical (60 Hz) artifact, respectively. All data collection and 





Figure 5. Sensor Placement and Electrical Configuration (+/-) for ECG and ICG Recording.  
Note: Subscripts indicate lead number. G = Ground, omitted in this investigation. 
 
Analysis of the ECG waveform produces estimates of HR and HRV. HR is defined as the 
average number of beats over a period of time (e.g., beats per minute) measured using a count of 
R waves observed in that period. In contrast, HRV is defined as the variability in the inter-beat 
interval (IBI) between R waves measured using either time or frequency domains. The frequency 
domain (expressed in Hz) is most appropriate for assessing changes over shorter periods of time 
(Berntson et al., 1993b). HRV requires a minimum of number of breath cycles (typically 10), 
which takes between 30 seconds and 60 seconds for most individuals. This method produces two 
main frequency ‘bands’ that represent differing levels of autonomic control.
2
 The low-frequency 
band (LF; 0.05-0.15 Hz) is associated with combined sympathetic and parasympathetic 
influences (coactivation), whereas the high-frequency band (HF; 0.15-0.4 Hz) is associated with 
parasympathetic control of the heart (Berntson et al., 1997). The HF band is the metric of an 
                                                 
2
 A third band exists at the very low-frequency range (VLF; 0.003-0.05 Hz), which represents 

















chronotropic phenomenon called respiratory sinus arrhythmia (RSA), a feature of independent 
parasympathetic control of the heart.  
ICG necessitates ECG (Berntson et al., 2007, Sherwood, 1993). The Q and R waves in 
the ECG signal establish cardiac landmarks that can be fitted to the two ICG waveforms, Z0 
(basal thoracic impedance) and dZ/dt (1
st
 derivative of Z0). Figure 6 presents prototypical 
examples of ICG waveforms as they relate to the QRS complex.  
 
 
Figure 6. Relationships Among ECG and ICG Signals and Corresponding Landmarks 
Note: PEP = Pre-ejection Period; LVET = Left Ventricular Ejection Time; Adapted from 
Berntson et al. (2007). 
 
There are two landmark points in the dZ/dt signal (i.e., B and X points) from which 
physiological cardiac function can be derived. The B point is located at the primary inflection in 
the waveform marking ventricular ejection (Lozano et al., 2007). Pre-ejection period (PEP) is 
calculated as the time between Q onset and the B point. The X peak is the lowest point in the 
dZ/dt signal and marks closure of the aortic valve and the end of ventricular ejection. Left 
ventricular ejection time (LVET) is calculated as the time between the B and X points. Both PEP 
and LVET are indices of cardiac contractility and thus relate to sympathetic control.  
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In the present study, RSA and PEP were used to calculate indices of CAB and CAR as 
defined by Berntson et al. (2008). Specifically, the CAB dimension is quantified as the 
difference between normalized (z-score transformed) indices of SNS and PNS activation at a 
given point in time, such that CAB = zHF – [(-1)zPEP]. Conversely, the CAR dimension is 
quantified as the sum of normalized indices of SNS and PNS activation at a given point in time, 
such that CAR = zHF + [(-1)zPEP]. In these calculations, normalization is required due to 
scaling differences between these measures. Inversion of PEP is required due to the negative 
correlation between this measure and SNS activity. Although CAB and CAR enable delineation 
of SNS and PNS reactivity, a more fine-grained method for measuring SNS responses is 
warranted due to the mounting evidence for SNS dysregulation in MetS (e.g., Licht et al., 2013). 
Oscillometric Blood Pressure (OBP) 
While measures of cardiac reactivity are available from ECG and ICG, measures of 
vascular reactivity can only be obtained by recording peripheral BP. Peripheral PB was recorded 
oscillometrically using an Oscar 2 Ambulatory Blood Pressure Monitor provided by SunTech 
Medical (Morrisville, NC). This technique records pressure oscillations in an inflated pneumatic 
cuff produced by a depressed artery (Babbs, 2012). An adjustable, inflatable nylon cuff was 
placed around the patient’s left upper arm at the level of the heart. OPB was measured once at 
baseline and at 5-minute intervals through out the experimental procedure. The Oscar 2 device 
automatically monitors and calculates systolic (SBP) and diastolic blood pressure (DBP), from 
which mean arterial pressure (MAP) and total peripheral resistance (TPR) can be determined. 
MAP is calculated from systolic and diastolic estimates such that MAP = 2(DBP/3) + SBP/3. 




Anxiety and Depression 
The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) is a 14-
item measure of anxiety and depression that has been used extensively in medical and primary 
care settings. Items on the scale address current physiological and psychological symptoms (e.g., 
I get a sort of frightened feeling like 'butterflies' in the stomach). Respondents provide ratings on 
a four-point Likert scale with variable anchors based on the extent to which they have 
experienced that symptom within the past week. The instrument contains two subscales of even 
length, including anxiety (HADS-A) and depression (HADS-D). Raw scores are summed to 
represent normal (0-7) borderline abnormal (8-10) and abnormal (11-21) levels of anxiety and 
depression, respectively. The psychometric properties of the HADS have been scrutinized in a 
number of populations and have been found to be excellent. Bjelland, Dahl, Haug and 
Neckelmann (2002) concluded that the internal consistency of the two subscales are very good to 
excellent (HADS-A α = .68-.93, HADS-D α = .67-.90) and that estimates of convergent validity 
indicate strong positive correlations with similar measures (r’s = .49-.83). Sensitivity and 
specificity of the instrument were in optimal balance at a score of 8 or above.  
Coping Style 
The Brief Coping Scale (Brief COPE; Carver, 1997) is a 28-item measure of coping style 
that has been used in both stress and health outcome research. Items on the scale represents a 
method for coping with life stress (e.g., I've been taking action to try to make the situation 
better). Respondents rate the extent to which they use each method on a five-point Likert scale (1 
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= I haven’t been doing this at all, 4 = I’ve been doing this a lot). Scoring yields 14 two-item 
subscales with higher scores indicating greater use of that strategy. Subscales include Behavioral 
Disengagement, Denial, Self-distraction, Self-blame, Substance Abuse, Active Coping, Positive 
Reframing, Planning, Humor, Acceptance, Religion, Emotional Support, Instrumental Social 
Support, and Venting. No procedure exists for creating second-order composite or factor scores; 
however, the author indicates that these scales can be organized within a second-order structure 
based on patterns evident in the observed responses. Such efforts have been undertaken in 
previous research to identify patterns in passive, active, and avoidant coping (Litman, 2006; 
Marroquín, Fontesc, & Scilletta, 2010; Mitchell, MacLeod, & Cassisi, in press). The Brief COPE 
has demonstrated adequate to very good internal consistency (all but one subscale   .60) and 
test-retest reliability (r’s = .46-.86). 
Quality of Life 
The World Health Organization Quality of Life – Brief Version (WHOQOL-BREF; The 
WHOQOL Group, 1996) is a 26-item quality of life measure in adults that has been implemented 
in a variety of settings internationally. It was developed as a short form for the longer 100-item 
version. Items on the scale (e.g., To what extent do you feel your life to be meaningful?) address 
current level of functioning across four biopsychosocial domains (Physical, Psychological, 
Social, Environmental). Respondents provide ratings on a five-point Likert scale with variable 
anchors based upon their experience within the previous two weeks. Scoring yields four domain 
scores with higher scores indicating higher quality of life in that domain. These scores may then 
be standardized using a 0-100 scale for ease of comparison. The WHOWOL-BREF has 
demonstrated adequate to very good psychometric properties, with ’s ranging from 0.68 to .82 
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across all domains. The discriminant and construct validity have been judged to be very good. 
The WHOQOL-BREF is correlated highly with similar measures of quality of life and can 
differentiate those with high and low quality of life as defined by independent criteria.  
Health Behavior and Treatment Adherence 
 To account for personal and contextual factors in illness, measurement of health behavior 
and treatment adherence is necessary. Measuring health behavior and treatment adherence is 
challenging for a number of reasons. First, the nature of medical interventions means the specific 
treatment recommendations and needs for each individual will be different. Additionally, the 
progression of an illness means treatment recommendations change over time; whereas one line 
of treatment may be easy to follow (i.e., early in the progression of an illness), a different line of 
treatment may present more extensive challenges. Despite these challenges, several themes in 
health behavior and adherence can be reliably quantified throughout one’s treatment. Current 
perspectives on measuring treatment adherence underscore the need for multiple methods of 
measurement that include combined objective and patient-reported measures (Riekert, 2006; 
WHO, 2003). 
Body Mass Index  
Participant’s body mass index (BMI) was recorded as a marker of relative weight. BMI is 
defined as the quotient of mass in kilograms (kg) and height in meters squared (m
2
). Height and 
weight were collected from patient medical records obtained on the day of data collection.  
Physical Activity 
Participant’s level of physical activity was measured with The International Physical 
Activity Questionnaire – Short Form (IPAC-S; Ainsworth et al., 2000). The IPAC is an eight-
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item self-report inventory that measures recent patterns in physical activity in a number of 
domains (e.g., work, leisure, exercise). Items on the scale include questions that address 
frequency of physical activity (e.g., During the last 7 days, on how many days did you do 
vigorous physical activities like heavy lifting, digging, aerobics, or fast bicycling?). Scoring 
protocol provides both categorical measures across individuals (low, moderate, high activity 
individuals) and continuous measures of physical activity across activity intensity (walking, 
moderate, vigorous activity). The continuous measures are in the unit of Metabolic Equivalent of 
Task-minutes (MET-minutes) per week. MET-minutes are useful to quantify physical activity 
because they are standardized to account for the intensity of activity. Higher MET-minute scores 
are indicative of greater physical activity. A number of studies support the psychometric 
properties of the IPAC-S. Estimates of internal consistency and test-retest reliability of the 
categorical outcomes are very good (Spearman’s  = .64-.79) and the measure also correlates 
highly with objective measures of physical activity (Craig et al., 2003). 
Smoking Status 
Participant’s smoking history was assessed by self-report. Smoking behavior was 
quantified categorically by status (current smoker, previous smoker, never smoked) and 
continuously by a count the number of cigarettes smoked per day for current smokers. 
Alcohol Use 
Participant’s use of alcohol was assessed with The Alcohol Use Disorders Test (AUDIT; 
Saunders, Aasland, Babor, de la Fuente, & Grant, 1993). The AUDIT is a 10-item instrument 
developed by the World Health Organization to assess drinking behavior in health care settings. 
Items on the scale address frequency, amount and problems in drinking behaviors (e.g., How 
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often do you have a drink containing alcohol?). Respondents provide ratings on a five-point 
Likert scale with variable anchors based on their typical use of alcohol. The AUDIT yields a 
single score ranging from 0 to 40, with higher scores indicating maladaptive alcohol use. The 
authors suggest that a score of 8 can be used as a cut-off for problematic drinking. The AUDIT 
has demonstrated good internal consistency ( = .62-.78), and very good test-retest reliability (r 
= .86). 
Medication Adherence 
The Morisky Medication-Taking Adherence Scale – Eight Item Version (MMAS-8; 
Morisky et al., 2008) is a widely used revised version of an earlier four-item scale used to assess 
adherence to medication regimens. Each item on the scale asks the respondent about his or her 
typical use of medication (e.g., Over the past two weeks, were there any days when you did not 
take your medicine?). Respondents answer either “yes” or “no” to each item. A composite score 
of summed positive responses is then calculated. Morisky et al. (2008) report the MMAS-8 
demonstrated good internal consistency ( = 0.83) and can discriminate between clinical 
outcomes in hypertension (i.e., those who demonstrate BP control, versus those who do not). 
Although it was developed originally for hypertensive medication adherence, the MMAS-8 has 
been utilized in diabetic populations with similar levels of success (Wang, Lee, Tang, Toh, & Ko 
2012). The MMAS-8 has been shown to correlate highly with pharmacy refill rates (Krousel-
Wood et al., 2009). 
Procedure 
 The experimental procedure was developed to take place in the context of a primary care 
clinic and included three phases: intake (consent documentation and sensor placement), 
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physiological recording (baseline period, two counterbalanced stressor tasks, and recovery 
periods following each task), and checkout (sensor removal, self-report assessment, and 
debriefing).  
Participants were recruited from the patient population at UCFH. Eligible patients were 
identified prior to their arrival at the clinic during routine clinical consultations between the 
investigator, attending physicians, and medical assistants. This consultation is a standard of 
practice for integrated healthcare services. Upon presenting for treatment and completing clinic 
check-in procedures, patients were escorted to the examination area where the medical assistant 
collected routine medical data (height, weight, vital signs). 
At that time, the investigator notified the patient about the study, provided an abridged 
study description, and invited the patient to participate. Regardless of the participant’s decision 
to participate, the patient’s healthcare appointment progressed as usual. In most cases, patients 
interested in participating were scheduled for a follow-up appointment to accommodate 
scheduling and availability restrictions. 
Phase I: Informed Consent and Preparation 
 The first element of Phase I was provision of a full description of the study procedures 
and potential risks and benefits of participation. This conversation occurred at the time of intake 
and included a broad overview of the topic of the study. This conversation did not include 
specific information about the study hypotheses. Following this description, participants were 
asked to provide their verbal consent to participate. Each participant was assigned a three-digit 
number to serve as an anonymous identifier throughout data collection and analysis. Each 
participant was randomized to one of two experimental conditions, which determined the order 
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in which stressor tasks were administered (see Phase II, below). Random assignment was 
completed using an virtual random number generator (www.random.org). 
 The second element of the intake phase was the preparation of the surface recording sites 
for ECG and ICG sensors and the attachment of the OBP cuff. Site preparation included a 
thorough cleansing of the skin using an alcohol pad. Next, sensors were placed on the skin and 
connected to the MindWareMobile device, which was secured to a belt containing the OBP 
monitor. Finally, the OBP cuff was placed around the participant’s arm and the device belt is 
secured to the participant’s waist.  
Phase II: Physiological Measurement 
 Physiological measurement began with a habituation period lasting five minutes. This 
period facilitated physiological habituation to the experimental environment and stabilization of 
physiological signals. The final minute of the habituation was used as a baseline for data 
analyses. This approach is generally superior to calculating change scores (Berntson, 2014, 
personal communication). The habituation period was tracked with a stopwatch, and start and 
end times were recorded using a standardized external timepiece. These times were then 
converted to a cumulative run-time to permit synchronization of event markers and signals 
collected in the experiential procedure.  
 Physiological measurements were recorded during two counterbalanced stressor tasks: a 
mental arithmetic task and a semi-structured health and wellness interview (see Appendices A 
and B, respectively). Counterbalancing of the stressors was used to help attenuate order effects in 
physiological activation. The mental arithmetic task involved two standardized procedures (i.e., 
Serial 7s and Mental Multiplication), each of which lasted one minute. In Serial 7s, participants 
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were asked to subtract seven from 100 and continue to subtract seven from each subsequent 
answer. In Mental Multiplication, participants were asked to multiply three by four and continue 
multiplying by three each subsequent answer. In both tasks, the investigator provided corrective 
feedback for incorrect answers and the participant was instructed to begin again. The health and 
wellness interview comprised five topics including medication adherence, diet, exercise, stress, 
and coping strategies. Each topic was discussed for approximately two minutes. The series of 
questions in each topic of conversation in this interview was uniform for each participant, but the 
specific content of each discussion was different, by necessity. The entire interview task lasted 
approximately 10 minutes. A five-minute recovery period followed each stressor task to 
encourage physiological signals to stabilize. As with the baseline period, stressor duration was 
tracked with a stopwatch, and start and end times were recorded using a standardized external 
timepiece. 
Phase III: Checkout 
Sensor removal was the first element of the checkout phase. The researchers removed the 
sensors and provided participants with cleansing wipes to remove any adhesive residue from 
their skin. The second element of the checkout phase was collection of self-report measures 
administered in paper-and-pencil format. The final element of the checkout phase was debriefing 
of the purpose and objectives of the experiment. Participants were provided more specific 
information about the research questions and were provided the opportunity to ask questions of 
the investigators. All participants received a debriefing form containing an additional written 
description and contact information for the research team and university review board.  
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Data Examination, Screening and Replacement 
The investigator examined the entire data set prior to initiating data analyses in 
accordance with recommendations by Tabachnick and Fidell (2013). During this process, it was 
discovered that several data points were missing or unavailable for analysis. The majority of 
these observations were related to medical data collected from patient records. These 
observations generally included measures of blood lipid and/or glucose levels, and were 
unavailable because either (1) routine collection of these values were not medically necessary as 
determined by the treating physicians, or (2) the values were no longer current (i.e., collected 
longer than 2 weeks prior to the visit). In light of these missing values, between-group 
comparison of these variables and examination of MetS as a continuous indicator was not 
feasible in the present study. The remaining missing data points were identified in self-report 
measures. Specifically, 11 cases contained missing values, with 1-7 observations missing per 
case (approximately 0.9% of the self-report data). These data, missing at random (MAR), were 
estimated and replaced via maximum likelihood (FIML) procedures in Mplus (Version 7.11, 
Muthén & Muthén; Los Angeles, California). In Mplus, multiple imputation for a set of variables 
with missing values is carried out using Bayesian analysis, creating a full dataset that can be used 
in subsequent analyses (Muthén & Muthén, 2012). FIML estimation is the preferred method for 
data replacement because it is built upon robust procedures that incorporate casewise likelihood 
estimation, thereby reducing standard error values (Enders & Bandalos, 2001).  
The resulting data set was then checked visually and statistically for multivariate 
normality and for violations of the assumptions of the general linear model. Several of the self-
report independent variables were positively skewed. Specifically, all MET-minute variables and 
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the AUDIT total score demonstrated positive skewness, with values of 2.31–5.44. To correct for 
these findings, we discarded the continuous scores derived from these measures and relied on 
categorical scoring, as described in the Measures section, above. All dependent variables were 
observed to be approximately normal (skewness < |1|).  Examination of normal Q-Q plots and 
residual scatter plots suggested that these variables did not violate the assumptions of the general 
linear model.  
Physiological Signal Processing 
 Signals were processed visually and digitally on a desktop computer using MindWare’s 
BioLab, ICG, and HRV Analysis software version 3.1.1. Prior to processing, event markers 
corresponding to the beginning and end of each of the baseline, recovery, and experimental 
periods were inserted manually into the data file. ECG and dZ/dt signals were digitized using a 
band pass filter with a low cutoff of .50 Hz and a high cutoff of 45.0 Hz. The Z0 signal was 
digitized using a low pass filter with a cutoff of 10 Hz. Data were obtained and recorded by 
examining the signal between the start and end event markers inserted via synchronized, 
cumulative run-time of each individual’s unique experimental procedure. For the Health and 
Wellness task, we utilized data from the full two-minute epoch of each interview segment. For 
the Mental Arithmetic task, we utilized data calculated from the one-minute epoch for each 
stressor. 
With regard to HRV calculation, spectral analysis followed a Hamming windowing 
function, with the VLF (.003-.04 Hz), LF (.040-.12 Hz) and HF (.12-.42 Hz) bands pre-set across 
all participants. The Z0 signal from ICG recording was used as a respiration signal for all HRV 
analysis in order to confirm that respiratory sinus arrhythmia occurred in the appropriate HF 
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frequency band. HRV analysis involved assessment of mean R-R peak variability (HF HRV, or 
RSA) as well as the standard deviation of normal R-R intervals (SDNN). 
With regard to ICG calculation, metrics of Z0 and dZ/dt were calibrated at .10 volts/Ohm 
and 1.00 Volts/Ohm/Second, respectively, with a blood resistivity constant of 135. The Q point 
calculation method was minimum value of the K-R interval where K=35. LVET windowing 
followed the Farmingham method with minimum and maximum offset threshold of 200 and 600 
milliseconds, respectively. B-point calculation was executed using the 55% plus a constant of 4 
procedure, as recommended by Lozano et al. (2007). Stroke volume was calculated using the 
Kubicek method. A 60 Hz notch filter was used during all signal processing procedures. 
Initially, signal processing involved removal of movement artifact from the raw ECG 
signal. Movement artifact was confirmed through examination of X-, Y-, and Z-axis actigraphy 
housed within the mobile monitoring unit. As a component of artifact removal, R-peak accuracy 
was assessed and corrected as needed. Upon verification of accurate R-peak placement for all 
data segments, automated analyses of HRV and ICG signals were initiated. All output variables 
from these automated analyses were then verified manually based on recommendations from 
Lozano et al. (2007).   
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CHAPTER THREE: RESULTS 
Sample Characteristics 
Within the final sample, we examined several characteristics of each experimental group 
that have the potential to impact physiological performance. These variables were selected on the 
basis of theoretical mechanisms underlying physiological performance or because previous 
research has indicated that particular variable may have such an effec. Table 4 contains 
descriptive and demographic characteristics for the full sample (N=50), stratified by 
experimental group. Table 4 also contains between-group comparisons on variables not directly 
included in establishment of MetS diagnosis.  
Table 4. Sample Characteristics by Experimental Group. 
 Experimental Group  
 Healthy Control 
(N=25) 
Metabolic Syndrome 




Mean Age (SD) 52.04 (18.37) 60.60 (14.00) 3.43 (1,49) .075 
Female Sex (N, %) 20, 80% 14, 56% –  – 
Race     
Caucasian (N, %) 19, 76% 13, 52% –  – 
Latino/a (N, %) 3, 12% 5, 20% –  – 
Black (N, %) 2, 8% 4, 16% –  – 
Asian (N, %) 1, 4% 3, 12% –  – 
Mean BMI (SD) 25.99 (5.17) 31.81 (6.60) 12.09 (1,49) .001 
Mean # Medical Problems (SD)  5.64 (0.82) 9.28 (1.01) 7.73 (1,49) .008 
Mean # CV Medications (SD) 0.32 (0.75) 1.28 (0.98) 15.15 (1,49) <.001 
Note:  BMI = Body mass index; CV = Cardiovascular 
With regard to race, we examined the relative proportions of race within the experimental 
groups using chi-square test of independence and found no difference between the HC and MetS 
groups, χ
2
 (3)=3.29, p=.349. With regard to sex, there is considerable evidence that rate of MetS 
diagnosis varies by sex and that sex influences patterns of cardiovascular responses (Ordaz & 
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Luna, 2012; Stoney, Davis, & Matthews, 1987). As such, we chose to include sex as an 
independent between-subjects variable or, unless otherwise noted, as a covariate in analyses 
examining either experimental group membership or CV activity. We also controlled for medical 
complexity (i.e., number of medical problems) in analyses that examined between-subject 
differences. This decision was based on the observed between-group differences, and findings in 
the literature that suggest individuals with chronic or advanced medical diagnoses may present 
with unique physiological profiles (Manganelli et al., 2002; Wakkee, Thio, Prens  Sijbrands, & 
Neumann, 2006). 
In the process of data collection, we tracked the use of medications known or intented to 
alter or adjust CV functioning, including the broad class of antihypertensive medications. The 
majority of the sample (52%) were not on any CV medication with smaller proportions 
prescribed one (24%), two (16%), and three (12%) CV medications. Table 5 provides an 
overview of medication prescription in both the HC and MetS groups. 
Table 5. Number of Individuals Prescribed CV Medications by Experimental Group 
 Experimental Group   Experimental Group 
Medication HC MetS  Medication HC MetS 
ACE Inhibitors 0 7  NDH CCB 0 0 
A2R Blockers 3 7  DH CCB 0 4 
Diuretics – –  Beta Blocker 0 5 
Thiazide 1 6  Alpha Blocker 1 3 
Loop 0 0  Antiarrythmics 0 0 
Aldasterone Blocker 2 0  Stimulants 1 0 
Note: HC = healthy control; ACE = angiotensin converting enzyme; A2R = angiotensin II 
receptor; NDH = non-dihydropyridine; DH = dihydropyridine; CCB = calcium channel blocker 
 
 Whereas several of these drugs work primarily on the physiology of the vascular system 
(e.g., ACE inhibitors), others work primarily on the heart cycle (e.g., beta blockers). In addition, 
several of these medications (e.g., diuretics) bring about systemic changes that comprehensively 
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alter the cardiovascular system, making it difficult to control for the global impact of these 
various agents. Therefore, in analyses examining either cardiac (e.g., CAB, CAR, PEP), or 
vascular functioning (e.g., TPR), we used as covariates only those medications that have direct 
cardiac or vascular implications, respectively. 
Examination of Study Aims and Tests of Experimental Hypotheses  
Aim 1: Validate the Relationship Between CAC and MetS 
Hypothesis 1: CAC will predict concurrent medical and mental health concerns 
 Following Berntson et al. (2008), binary logistic regression was employed to predict 
diagnosis of DM2 and CVD from baseline CAB and CAR scores. The DM2 group (N=11) 
included all individuals with a current diagnosis. The CVD group (N=9) included all individuals 
with recorded diagnosis of coronary artery disease, congestive heart failure, or arrhythmia, as 
described by the American Heart Association. Both baseline CAB and CAR scores and an 
interaction term (CAB  CAR) were entered into the regression equation in a hierarchical 
fashion, with CAB preceding CAR in the prediction of DM2 diagnosis, and CAR preceding 
CAB in the prediction of CVD. To avoid multicolinearity, the individual components of the CAB 
and CAR variables were not included in these models. Observed groups and predicted 
probabilities plots were generated to identify potential outliers; none were detected. Findings 
from the final model blocks are described in-text. Findings form the full models are presented in 
Table 6. 
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Table 6. Full Model Logistic Regression Analysis Predicting Diagnosis of Diabetes and 
Cardiovascular Disease from CAB and CAR Scores. 
Type 2 Diabetes Diagnosis (N=11) 
Predictor β SE β Wald df p e β 
(Constant) -1.319 0.375 13.646 1 .000 0.267 
CAB -0.003 0.226 0.000 1 .991 0.997 
CAR 0.074 0.315 0.054 1 .816 1.076 





 df p 
 
Overall Model Evaluation   1.505 3 .651  
H-L Goodness of Fit   11.848 8 .158  
       
Cardiovascular Disease Diagnosis (N=9) 
Predictor β SE β Wald df p e β 
(Constant) -2.040 0.556 13.451 1 .000 0.130 
CAR -0.786 0.388 4.115 1 .042 0.456 
CAB -0.562 0.355 2.501 1 .114 0.570 
CAB  CAR -0.426 0.333 1.633 1 .201 0.653 
Test   χ
2
 df p  
Overall Model Evaluation   8.275 3 .041  
H-L Goodness of Fit   8.745 8 .364  
Note: H-L = Hosmer-Lemeshow 
 None of the logistic models predicting diagnosis of Type 2 Diabetes was significant; 
however, the final model iteration predicting diagnosis of CVD was significant, Nagelkerke 
R
2
=.250, and correctly classified 86% of all CVD cases. In this model, CAR was a significant 
negative indicator (β=-0.562), suggesting decreased CAR scores are associated with an increased 
likelihood of being diagnosed with CVD. The Hosmer-Lemeshow goodness-of-fit test was non-
significant for this model, indicating that this model is appropriately specified, and observed 
group membership did not deviate from the expected count predicted by the model. This finding 
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is consistent with previous research provided by Berntson and colleagues that indicate 
diminished CAR scores are associated with previous MI.  
Subsequently, a series of hierarchical linear regression analyses was employed to 
determine if CAC variables, including CAB, CAR, and individual measures of the cardiac cycle 
predict self-reported quality of life, anxiety and depression scores. We chose to include 
individual cardiac measures in the model to account for independent activation of sympathetic 
and parasympathetic branches, as CAB and CAR capture reciprocity and co-activation of these 
branches, respectively. To account for potential experimental group differences (HC vs. MetS), a 
dummy-coded dichotomous variable was entered into the first block of the regression. Baseline 
CAB and CAR were included in the second block, and baseline measures of PEP, RSA, LVET, 
and CO were included in the final block. Although SV was originally included in the model, it 
was removed to avoid multicolinearity. Mahalonobis distances were computed to identify 
outliers; none were detected. Table 7 contains descriptive statistics and zero-order Pearson 
correlations among all observed variables in this model. Additional descriptive statistics for 
study variables are presented in Appendix A. 
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Table 7. Descriptive Statistics and Zero-order Correlations Among Physiological and Self-report Health Measures in the Full 
Sample. 
 1 2 3 4 5 6 7 8 9 10 11 12 13 
1. CAB –             












 –          
5. LVET -.13 .12 -.17 -.03 –         
6. SV -.14 .08 -.16 -.07 -.50
***
 –        
7. CO -.27
*




 –       
8. ANX -.26 .05 -.24 -.18 -.10 .09 .12 –      
9. DEP -.09 -.03 -.06 -.09 -.01 .04 .05 .63
***
 –     




 –    






 –   








 –  











              
Descriptives CAB CAR PEP RSA LVET SV CO ANX DEP QLPH QLPS QLS QLE 
Mean  0.00 0.00 92.76 4.86 304.80 257.64 17.85 6.94 4.44 14.33 14.33 13.38 16.04 
SD 1.61 1.19 24.00 1.15 71.94 106.73 7.05 3.55 2.98 3.22 2.84 3.55 2.86 
Minimum -3.13 -3.78 50.00 2.66 158.00 94.47 6.20 1.00 0.00 7.43 7.33 6.67 9.00 
Maximum 3.85 2.92 142.00 7.58 410.00 553.33 37.38 14.00 13.00 20.00 19.33 20.00 20.00 
Note: 
***




 <.05;  CAB = Cardiac Autonomic Balance; CAR = Cardiac Autonomic Control; PEP = pre-ejection 
period; RSA = respiratory sinus arrhythmia; LVET = left ventricular ejection time; SV = stroke volume; CO = cardiac output; ANX = 
Hospital Anxiety and Depression – Anxiety Scale Score; DEP = Hospital Anxiety and Depression – Depression Scale Score; QL-PH 
= WHO Quality of Life–Brief–Physical Domain; QLPS = WHO Quality of Life–Brief–Psychological Domain; QLS = WHO Quality 
of Life–Brief –Social Domain; QLE = WHO Quality of Life–Brief–Environmental Domain. 
 42 
With regard to quality of life, only one model reached significance. In the prediction of 
the Quality of Life-Environment Domain, both LVET (β=0.369) and CO (β=-0.353) significantly 




=.14, F(5,44)=2.558, p=.041. These 
findings indicate that individuals with longer LVET and lower CO scored higher in this domain 
of QOL. Models predicting Physical Domain scores, F(5,44)=1.097, p=.375, Psychological 
Domain scores, F(5,44)=0.988, p=.436, and Social Domain scores, F(5,44)=1.676, p=.160 failed 
to reach significance. These findings indicate that the CAB, CAR, and individual measures of 
cardiac functioning did not predict these quality of life domains, while controlling for diagnosis 
of MetS.  
Regression models predicting anxiety, F(5,44)=1.056, p=.728, and depression, 
F(5,44)=0.674, p=.645, failed to reach significance. These findings indicate that the CAB, CAR, 
and individual measures of cardiac functioning did not predict these self-reported anxiety or 
depression scores, while controlling for diagnosis of MetS. Collectively, these results provide 
only partial support to our first experimental hypothesis.  
Hypothesis 2: Individuals with MetS will evidence lower CAC at baseline 
Prior to examination of baseline CAB and CAR, we performed a 2 (experimental group) 
 2 (sex) multivariate analysis of covariance (MANCOVA) to determine differences in baseline 
PEP and RSA. We controlled for number of medical problems and for medication use by 
entering as a dummy-coded variable patients who were and were not prescribed beta-blockers. In 
reviewing multivariate results, we failed to detect main effects for group, Λ=.958, F(2, 
43)=0.933, p=.401, or sex, Λ=.991, F(2, 43)=0.189, p=.828, suggesting that neither baseline PEP 
nor RSA were significantly different between these sets of participants. 
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Subsequently, we performed a 2 (experimental group)  2 (sex) MANCOVA to identify 
differences in baseline CAB and CAR scores. We controlled statistically for baseline PEP and 
RSA scores as well as number of medical problems and medication use, as noted above. We 
failed to detect main effects for group, Λ=.979, F(2, 43)=0.464, p=0.632, or sex, Λ=.993, F(2, 
43)=0.153, p=.859, suggesting that neither baseline CAB nor baseline CAR scores were 
significantly different between these groups, even when controlling statistically for medical 
problems and medication use. These findings do not support experimental hypothesis 2.  
Aim 2: Examine CAC among patients with MetS during a standardized stressor. 
Hypothesis 3: Patients with MetS will display lower CAC scores during standardized stressors. 
Prior to examining group differences in calculated CAC scores during any of the 
experimental stressors, our first task was to verify that group differences exist in the constituent 
variables that comprise the computed CAB and CAR scores. These analyses also helped us 
verify the effectiveness of our experimental manipulation. To this end, we executed paired-
sample t-tests across the full sample to examine differences in PEP and RSA between baseline 
and each segment of the experimental manipulation. We also conducted a 2 (experimental group) 
 2 (sex) MANCOVA to determine differences in PEP and RSA scores during both the mental 
arithmetic and health and wellness stressors. In the MANCOVA analysis, we controlled for 
number of medical problems and medication use by entering as a dummy-coded variable patients 
who were and were not prescribed beta-blockers. We also included baseline PEP and RSA scores 
as covariates during examination of experimental stressors, following Bernston et al. (2008). 
Descriptive statistics for variables included in these analyses are presented in Appendix A. 
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Findings from paired-sample t-tests suggested that across the full sample, our 
experimental manipulations were associated with significantly lower PEP values relative to 
baseline, providing evidence that our experimental manipulation was effective in eliciting a 
physiological stress response (see Table 8).  
Table 8. Tests of Differences in PEP and RSA Between Baseline and Experimental Task 
Segments Across the Full Sample (N = 50). 
 t df p 
Health and Wellness Interview    
Medication Segment    
Baseline – Task Δ PEP 2.216 49 .031 
Baseline – Task Δ RSA -1.193 49 .239 
Diet Segment    
Baseline – Task Δ PEP 3.314 49 .002 
Baseline – Task Δ RSA -1.087 49 .282 
Exercise Segment    
Baseline – Task Δ PEP 1.436 49 .157 
Baseline – Task Δ RSA -0.494 49 .632 
Stress Segment    
Baseline – Task Δ PEP 1.866 49 .068 
Baseline – Task Δ RSA -0.693 49 .492 
Coping Segment    
Baseline – Task Δ PEP 1.770 49 .083 
Baseline – Task Δ RSA 0.140 49 .889 
Mental Arithmetic    
Serial 7s Segment    
Baseline – Task Δ PEP 2.393 49 .021 
Baseline – Task Δ RSA 1.946 49 .057 
Multiplication Segment    
Baseline – Task Δ PEP 2.665 49 .010 
Baseline – Task Δ RSA 0.580 49 .565 
Note: PEP = Pre-ejection period; RSA = Respiratory sinus arrhythmia 
Multivariate results by experimental group revealed a significant main effect for group, 
Λ=.469, F(14, 29)=2.348, p=.025, partial η
2
=.531, but not for sex, Λ=.624, F(14, 30)=1.250, p = 
.295. Findings from planned comparisons within this set of analyses are presented in Table 9. 
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Table 9. Tests of Between-subject Differences in PEP and RSA During Individual Segments of 
the Experimental Task. 
 F df p Partial η
2
 
Health and Wellness Interview     
Medication Segment     
PEP 6.763 1, 42 .013 .139 
RSA 1.011 1, 42 .320 .024 
Diet Segment     
PEP 8.562 1, 42 .006 .169 
RSA 0.102 1, 42 .751 .002 
Exercise Segment     
PEP 0.333 1, 42 .567 .008 
RSA 1.137 1, 42 .292 .026 
Stress Segment     
PEP 0.919 1, 42 .343 .021 
RSA 3.591 1, 42 .065 .079 
Coping Segment     
PEP 0.187 1, 42 .668 .004 
RSA 0.061 1, 42 .806 .001 
Mental Arithmetic     
Serial 7s Segment     
PEP 0.000 1, 42 .984 .000 
RSA 0.636 1, 42 .481 .012 
Multiplication Segment     
PEP 0.147 1, 42 .704 .003 
RSA 0.871 1, 42 .356 .020 
Note: PEP = Pre-ejection period; TPR = Total peripheral resistance 
After accounting for covariates described above, estimated marginal mean PEP values in 
the HC group were higher during the medication and diet segments, as compared to the MetS 
group, suggesting a greater sympathetic response in MetS during these segments. The group-by-
sex interaction failed to reach significance, Λ=.614, F(14, 29)=1.301, p=.263. 
We then performed a 2 (experimental group)  2 (sex) repeated measures MANCOVA 
to determine differences in CAB and CAR scores during the two mental arithmetic stressors. We 
controlled statistically for baseline CAB and CAR scores as well as number of medical problems 
and beta-blocker medication (dummy coded). We failed to detect main effects for group, 
Λ=.981, F(2, 41)=0.392, p=.678, or sex, Λ=.984, F(2, 41)=0.337, p=.716, suggesting that 
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contrary to our hypothesis, CAB and CAR scores during all segments of the standardized 
stressor tasks did not differ by experimental group or as a function of sex, when controlling for 
medication. Figure 7 depicts group CAB and CAR scores during the mental arithmetic stressors. 
 
Figure 7. Between-group Estimated Marginal Means of CAB and CAR Scores During the 
Mental Arithmetic Stressors 
 
Aim 3: Examine CAC Among Patients with MetS During a Health and Wellness Interview 
Hypothesis 4: Patients with MetS will display lower CAC scores during health interview. 
We performed a 2 (experimental group)  2 (sex) MANCOVA to determine differences 
in CAB and CAR scores during the five health and wellness interview segments. We controlled 
statistically for baseline CAB and CAR scores as well as number of medical problems and 
medication use (dummy-coded), as noted above. Overall, we failed to detect main effects for 
group, Λ=.931, F(2, 42)=1.561, p=.222, or sex, Λ=.928, F(2, 42)=1.634, p=.207, suggesting that 































even when controlling for medication use that has the potential to alter sympathetic cardiac 
control. Nonetheless, we did detect a segment-by-group interaction, Λ=.496, F(2, 42)=4.573, 
p=.001, partial η
2
=.504, suggesting CAC scores during interview segments differed as a function 
of experimental group.  
Follow-up multivariate tests of within-subjects effects confirmed this interaction, 
Λ=.893, F(8, 334)=2.440, p=.004, and univariate tests of within-subjects contrasts (i.e., changes 
over time) revealed that CAB scores across the HWI interview segments were significantly 
different between the MetS group and the HC group, F(1, 42)=11.974, p=.001, partial η
2
=.222. 
In addition, we found that CAR scores across the HWI interview segments were significantly 
different between the MetS group and the HC group, F(1, 42)=9.495, p = .004, partial η
2
=.184. 
Collectively, this pattern of findings permitted additional inspection of differences in CAB and 
CAR at each individual segment. 
Planned between-subjects comparisons (paired-samples t-tests corrected for multiple 
comparisons using the Bonferoni adjustment) across interview segments confirmed that CAB 
scores during the stress segment were significantly higher in the HC group as compared to the 
MetS group, p=.049. We also observed that CAR scores during the medication segment were 
significantly higher in the MetS group as compared to the HC group, p=.051.  MetS and HC 
groups did not respond differently during other interview segments, providing partial support for 
this hypothesis. Figures 8a and 8b depict CAB and CAR scores, respectively, across each of the 






Figure 8. Between-group Estimated Marginal Means of (a) CAB and (b) CAR Scores Across All 
Health and Wellness Interview Segments.  



































































Hypothesis 5: During experimental tasks, a CV “threat” response will be associated with MetS. 
 Binary logistic regression was used to predict MetS diagnosis from CV variables. 
Unanticipated discrepancies in the initiation of the Mental Arithmetic and Health and Wellness 
Interview tasks across participants limited our ability to verify that a particular BP measurement 
and TPR value was representative of physiological reactions to that task. Therefore, we used 
sequential points of measurement as an alternative method of estimation, serving as a proxy for 
on-going task engagement. We entered PEP, TPR, and an interaction term (PEP  TPR) 
hierarchically in blocks representing each of the measurement points, such that each block only 
contained the observed variables for that point in time (i.e., 300 [baseline], 600, 900, 1200, 1500 
and 1800 seconds). The interaction term was intended to depict the simultaneous cardiac and 
vascular changes that characterize the “threat” response. In the initial block, we also included 
dummy-coded variables accounting for medication prescriptions (beta-blocker and ACE 
inhibitor). Each block in the model included previous blocks to estimate the cumulative effect of 
these observations in the prediction of MetS. 
Table 10. Omnibus Chi-Square, Goodness-of-fit, and Classification Accuracy Derived from the 
Full Logistical Model Predicting Metabolic Syndrome through PEP and TPR. 
 Nagelkerke R
2
 % correct χ
2
 df p 
Block 1, Omnibus Model Test .000 52.4 .008 3 .998 
H-L Goodness-of-Fit   10.556 8 .228 
Block 2, Omnibus Model Test .225 54.8 7.730 6 .258 
H-L Goodness-of-Fit   6.558 8 .585 
Block 3, Omnibus Model Test .457 78.6 17.631 9 .040 
H-L Goodness-of-Fit   8.682 8 .370 
Block 4, Omnibus Model Test .538 78.6 21.665 12 .041 
H-L Goodness-of-Fit   5.962 8 .651 
Block 5, Omnibus Model Test .594 83.3 24.746 15 .053 
H-L Goodness-of-Fit   10.155 8 .254 
Block 6, Omnibus Model Test .804 92.9 38.747 18 .003 
H-L Goodness-of-Fit   3.110 8 .927 
Note: H-L = Hosmer-Lemeshow 
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Table 10 provides omnibus chi-square model tests as well as goodness-of-fit tests for 
each block in the model. Table 11 provides parameter estimates of all indicators entered into the 
full model. 
Table 11. Logistical Regression Parameter Estimates, Standard Errors, and Odds Ratio for the 
Full Logistical Model in the Prediction of Metabolic Syndrome from Measures of PEP and TPR. 
 β SE β Wald df p e β 
Null Model (Constant) 22.231 30.890 0.518 1 .472 4.516 
Block 1 (Baseline)       
PEP, 300 seconds 0.241 0.290 0.687 1 .407 1.272 
TPR, 300 seconds -0.291 4.067 0.005 1 .943 .748 
PEP  TPR 300 seconds -0.054 0.045 1.464 1 .226 .947 
Block 2       
PEP, 600 seconds -1.209 0.678 3.179 1 .075 .298 
TPR, 600 seconds -6.414 5.643 1.292 1 .256 .002 
PEP  TPR 600 seconds 0.166 0.109 2.350 1 .125 1.181 
Block 3       
PEP, 900 seconds -0.761 0.490 2.241 1 .120 .467 
TPR, 900 seconds -14.564 8.527 2.917 1 .088 .000 
PEP  TPR 900 seconds 0.168 .099 2.846 1 .092 1.183 
Block 4       
PEP, 1200 seconds -0.871 0.657 1.760 1 .185 .418 
TPR, 1200 seconds -9.001 8.763 1.055 1 .304 .000 
PEP  TPR 1200 seconds 0.103 0.116 0.779 1 .377 1.108 
Block 5       
PEP, 1500 seconds 0.414 0.329 1.586 1 .208 1.513 
TPR, 1500 seconds -7.018 4.486 2.448 1 .118 .001 
PEP  TPR 1500 seconds 0.077 0.049 2.455 1 .117 1.080 
Block 6       
PEP, 1800 seconds 1.859 1.067 3.034 1 .082 6.416 
TPR, 1800 seconds 29.617 16.870 3.082 1 .079 7.285 
PEP  TPR 1800 seconds -0.353 0.205 2.977 1 .084 .702 
Note: PEP = Pre-ejection Period; TPR = Total Peripheral Resistance 
Overall model chi-square tests reached significance, suggesting that the full model 
predicted diagnosis of MetS. Nonetheless, when individual indicators were examined, none of 
the Wald estimates in this model reached significance and therefore cannot be interpreted. This 
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pattern suggests that no single indicator variable significantly contributed to the full model, but 
that collectively, this series of variables adequately predicted group membership.  
The independent variables in this analysis were intended to serve as indicators of the 
“threat” response. Because they failed to reach significance, the interpretation of this model is 
not feasible. As such, an alternative method to understand the association between MetS and 
cardiovascular responses involves visual and statistical examination of group differences in PEP 
and TPR change scores at each point of measurement. To this end, we compared the 
experimental groups on change-from-baseline PEP and TPR at each point of measurement using 
2 (experimental group) X 2 (sex) repeated measures MANCOVA controlling number of medical 
problems and medication use (beta blocker, ACE inhibitor). Time points were used as the within-
subjects factor in the same fashion as noted above (i.e., at 600, 900, 1200, 1500 and 1800 
seconds). The 300-second point of measurement of PEP and TPR was used in the calculation of 
change scores and therefore was not included in the analysis.  
Contrary to expectations, findings from the MANCOVAs did not reveal a within-subjects 
main effect for group, Λ=.965, F(2, 31)=0.561, p=.357. The main effect for sex was also non-
significant, Λ=.936, F(2, 31)=1.066, p=.278. There was no within-subject main effect for 
measurement point, Λ=.804, F(8, 25)=0.761 p=.639, and neither the time-by-group interaction, 
Λ=.661, F(8, 25)=1.604, p=.174, nor the time-by-sex interaction reached significance, Λ=.719, 
F(2, 28)=1.223, p=.326. Collectively, these findings do not support our fifth experimental 
hypothesis.   
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Aim 4: Examine the Impact of CAC on Health Behavior and Treatment Adherence 
Hypothesis 6: CAC scores will be associated with health behavior and medication adherence 
 Prior to analyses, we examined the self-report outcome variables to address concerns 
related to violations of the general linear model, as described above. We determined that even 
when utilizing the well-supported AUDIT cut off score of ‘8’ to denote problematic drinking, 
cell size of the problematic drinking group was too small (N = 4) to analyze statistically. In 
conjunction with the significant skewness observed in the continuous AUDIT score, we removed 
this variable from the analytic plan. Additionally, we created a dichotomous variable from the 
physical activity group assignment due to initial findings revealing singularities in the 
multinomial regression Hessian matrix, typically indicating statistical separation in the DV. 
Separation is sometimes referred to as ‘perfect prediction,’ and occurs when one of the 
categorical outcome groups is explained entirely by one level of an indicator variable. In this 
case, the recommended approach is to re-specify the model by merging categories of the 
outcome variable or creating fewer groups (Gill & King, 2003). Because the groups were 
approximately equal in size, we created a dichotomous (median-split) variable based on the 
continuous physical activity scale, resulting in low- and high-activity groups. Finally, as 
described in the AUDIT scores, we found similar differences in smoking classification, with 
separate groups of current smokers (N = 5) and previous smokers (N = 11) creating too few cases 
in each cell for analysis. In this case, we collapsed responses to the smoking status question 
creating two groups, one comprising current and previous smokers and one comprising non-
smokers. 
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 We then performed a series of logistic regression analyses predicting smoking group (yes 
vs. no) and activity group (low vs. high) using sex and experimental group as initial covariates in 
block 1. Both baseline CAB and CAR as well as a CAB  CAR interaction term scores were 
entered into the regression equation in a hierarchical fashion in block 2. Subsequently, we 
performed a series of linear regressions predicting BMI and medication adherence score using 
sex and experimental group as initial covariates in block 1. As above, baseline CAB and CAR 
and a CAB  CAR interaction term were entered into the regression equation in block 2. 
Findings from the final model blocks are described in-text. Findings form the full models are 
presented in Tables 12 and 13. 
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Table 12. Full Model Logistic Regression Analysis Predicting Smoking Status and Low Physical 
Activity from CAB and CAR Scores 
Positive Smoking Status  (N=16) 
Indicator β SE β Wald df p e β 
(Constant) 0.199 0.753 .070 1 .791 1.221 
Sex -2.114 0.780 7.175 1 .007 .121 
Group 0.421 0.783 0.289 1 .591 1.524 
CAB -0.305 0.272 1.259 1 .262 .737 
CAR -0.687 0.356 3.730 1 .053 .503 
CAB  CAR -0.041 0.307 0.018 1 .894 .960 
Test   χ
2
 df p  
Overall Model Evaluation   15.671 5 .008  
H-L Goodness of Fit   6.799 8 .558  
 
      
Low Physical Activity (N=25) 
Indicator β SE β Wald df p e β 
(Constant) 0.545 0.671 0.661 1 .416 1.725 
Sex -0.250 0.663 0.142 1 .707 .779 
Group -0.756 0.620 1.483 1 .223 .470 
CAB -0.295 0.195 2.279 1 .131 .745 
CAR -0.083 0.264 0.100 1 .752 .920 
CAB  CAR 0.071 0.223 0.101 1 .751 1.073 
Test   χ
2
 df p  
Overall Model Evaluation   4.704 5 .448  
H-L Goodness of Fit   8.498 8 .386  
 
The full logistic model predicting physical activity failed to reach significance; however, 
as noted in Table 11, the full model predicting smoking status was significant, Nagelkerke 
R
2
=.269, and correctly classified 78% of all cases with affirmative smoking status. In this model, 
both participant sex (β=-2.114) and CAR (β=-0.687) were significant negative indicators, 
suggesting male gender and decreased CAR scores are associated with an increased likelihood of 
smoking status. The Hosmer-Lemeshow goodness-of-fit test was non-significant for this model, 
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indicating that this model is appropriately specified, and observed group membership did not 
deviate from the expected count predicted by the model.  
Table 13. Multiple Regression Estimates Predicting BMI and Medication Adherence from CAB 
and CAR Scores. 
 
β SE β B t p 
Body Mass Index 
     
(Constant) 21.449 3.651 – 5.992 .000 
Sex 6.448 1.923 .162 1.177 .246 
Group 2.263 1.794 .496 3.594 .001 
CAB 0.126 0.542 .031 0.233 .817 
CAR 0.428 0.761 .077 0.562 .577 
CAB  CAR 0.254 0.613 .056 0.400 .691 
Medication Adherence 
     
(Constant) 2.421 1.132 – 1.966 .054 
Sex -0.099 0.596 -.024 -0.165 .869 
Group 1.009 0.556 .265 1.813 .077 
CAB -0.273 0.168 -.229 -1.628 .111 
CAR 0.256 0.236 .158 1.083 .285 
CAB  CAR 0.177 0.190 .139 0.931 .357 
Note: CAB = cardiac autonomic balance; CAR = cardiac autonomic regulation 





=.16. Within this model, only group membership (β=2.263) was a 
significant predictor of BMI. With regard to medication adherence, the omnibus test of the full 
model in the prediction failed to reach significance, F(5,44)=1.562, p=.191. These findings 
should be interpreted with caution, however, because in both instances the null model remained 
significant with the inclusion of the hypothesized indicator variables. As such, we cannot 
conclude that these variables enhance prediction of BMI or medication adherence.  
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CHAPTER FOUR: DISCUSSION 
 
The purpose of this investigation was to further clarify the relationship between 
metabolic abnormalities and autonomic dysregulation as measured by variations in CAC. In 
support of this purpose, we used ambulatory ICG to measure physiological changes during 
engagement in psychosocial stressors among 50 patients with and without metabolic syndrome. 
We then compared these groups on a variety of cardiovascular measures to identify the extent to 
which patterns of sympathovagal reactivity may be implicated in MetS, and whether such a 
relationship may also impact health behavior and treatment adherence. To our knowledge, this is 
the first study to examine whether individuals with and without MetS differ in regard to CAC in 
the context of experimentally induced stress. We developed four aims to address our core 
research questions. Each of these aims will be discussed in turn. 
Our first aim was to verify the association between CAC and health status. In particular, 
we set out to replicate previous findings that suggest CAB and CAR are related to certain chronic 
conditions that develop as a result of MetS (i.e., type 2 diabetes and cardiovascular disease). We 
hypothesized that CAC indices would predict diagnosis of these conditions in our sample; this 
hypothesis gained partial support. As expected, CAR was a significant predictor of 
cardiovascular disease, lending support to the original work by Berntson et al. (2008). This 
finding indicated that within the full sample, individuals who evidenced a lower degree of co-
activation between sympathetic and parasympathetic systems were more likely to be diagnosed 
with cardiovascular disease. This association is conceptually and empirically well-supported, as 
diminished sympathovagal co-activation may restrict the dispositional nature with which one 
adapts to a stressor, and facilitating a cycle of maladaptive responding (Sloan et al, 1995). 
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Despite this significant outcome, CAB was not a significant predictor of type 2 diabetes, a 
finding that does not replicate the original work. There are likely several reasons for this null 
finding, the most salient of which may be related to consistency of diabetes management across 
the sample. While many measurements of HbA1C were missing from this sample, most of the 
existing values were below 7.5, suggesting a relatively high degree of control of this chronic 
condition and potentially decreased burden on the cardiovascular system.  
In an effort to further examine the relationship between CAC and health status, we also 
tested whether cardiovascular measures (including CAB and CAR) could predict self-reported 
measures of psychosocial distress and quality of life while controlling for MetS diagnosis. 
Contrary to our expectations, our models predicted only one of the quality of life domains 
(environmental). We found higher LVET scores and lower CO scores were associated with 
greater environmental quality of life. Higher LVET scores are often cited as a marker of 
decreased sympathetic cardiac control; likewise, CO, which is largely related to myocardial 
contractility
3
, may also serve as an indicator of sympathetic activation. These variables not only 
predicted quality of life in this domain, but also did so in an expected direction, such that lower 
sympathetic activation is associated with increased perceived environmental quality of life. Items 
in this scale pertain to physical safety and security, accessibility and quality of health care, and 
quality of physical environment, among others. It may be that individuals who respond with 
decreased sympathetic cardiac control are more likely to engage in practices that support this 
                                                 
3
 There are a host of additional variables that influence and/or change CO including pre-load, 
after-load and heart rate (Vincent, 2008). However, because contractility is often indicative of 
sympathetic cardiac control in non-exertive situations, it frequently denotes degree of 
sympathetic activation.   
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domain of quality of life. Our models did not predict anxiety or depression scores, however, 
running contrary to our hypothesis. Failure to detect differences in these models may be due to a 
relatively low degree of reported symptoms (i.e., restricted range) within these measures.  
Our second hypothesis within this aim was to examine baseline differences in CAC and 
related indices of sympathovagal activation between the MetS and HC groups. We hypothesized 
that the MetS and HC groups would differ both on individual measures of sympathetic (PEP) and 
parasympathetic (RSA) cardiac control, but also on the computed measures of CAB and CAR. 
Contrary to expectations, baseline CAB and CAR scores did not differ between groups, even 
when controlling for medication use and number of medical problems. Though unanticipated, 
this finding nonetheless provides important information with regard to reactivity of the 
experimental groups during experimentally induced stress. That is, this finding argues against the 
notion that cardiovascular status individuals with MetS are fundamentally different at rest. 
Instead, we submit that it is in the process of appraising and responding to external demands that 
meaningful alterations emerge. These alterations, in turn, may provide the foundation for 
negative health outcomes.  
Our second and third experimental aims were directed at understanding this possibility 
and were focused on examining CAC among patients with MetS during the two distinct 
experimental tasks. These tasks comprised standardized mental arithmetic as well as a structured, 
but flexible health and wellness interview. Prior to proceeding with these tests, we first verified 
the effectiveness of our experimental relationship by examining changes in key psychological 
variables across the full sample during the experimental task. We identified decreases in PEP 
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during a number of the task segments, providing initial indication that our experimental task 
elicited the expected response across the entire sample. 
We hypothesized that individuals with MetS would evidence lower CAB and CAR scores 
during the standardized Mental Arithmetic stressor. By virtue of the standardization, this stressor 
was intended to provide a point-of-comparison for subsequent experimental tasks. Our findings 
revealed that configuration of CAB and CAR responses to the arithmetic tasks were consistent 
with expectation, but these differences failed to reach statistical significance. It is unlikely that 
this null finding is an artifact of practice effects. Counterbalancing of experimental tasks was 
crucial in order to verify group differences were due not to passage of time, but to the specific 
experimental manipulation. The utility of using this stressor as a point-of-comparison is therefore 
crucial in the context of examining hypothesized between-group differences during the other 
stressors tasks. 
Indeed, we observed such differences during distinct segments of the health and wellness 
interview. These differences occurred both in PEP and RSA as well as the computed CAC 
variables. Specifically, PEP among HC participants became longer during the medication and 
diet segments, as compared to those with MetS. This difference was in the expected direction, 
suggesting that HC participants responded with decreased sympathetic activity in response to 
these segments.  
Moreover, we found significant group-by-segment interaction in both CAB and CAR 
scores that highlight how patterns of responses between experimental groups differed in the 
context of distinct interview segments. CAB scores in the HC group generally increased across 
the interview segments, peaking during the stress segment. The opposite pattern was observed in 
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the MetS group, which evidenced generally decreasing CAB scores, with the lowest value 
observed during the stress segment. That is, MetS participants demonstrated poorer 
sympathovagal balance when discussing their daily stress as compared to HC patients. This 
finding points to maladaptive psychological responses to an externally presented stressor (i.e., 
the interview questions), and it is potentially meaningful given its relevance to stress cues. It is 
possible that patterns of appraisal observed here may become chronic and can therefore place an 
individual at greater risk for negative health outcomes either by limiting the extent to which the 
individuals maintains allostasis, or by increasing allostatic load. It may also be the case that the 
topic presented during this experimental task provides a context in which the patient with MetS 
may avoid stress cues. 
Patterns of CAR scores during the interview segments were slightly different relative to 
the corresponding pattern of CAB scores. Among HC participants, CAR scores were the lowest 
in response to questions about medication adherence and trended upward thereafter, peaking 
during the stress segment. Again, the opposite pattern was seen in MetS patients with highest 
CAR scores observed during the medication segment. CAR scores then decreased gradually to 
their lowest point, observed during the stress segment. This pattern indicates coactive 
sympathovagal responses among MetS patients discussing medication adherence, in comparison 
to HC participants, who responded with a lesser degree of sympathovagal co-activation to the 
same questions. This finding, though unexpected, may support the notion that as medical 
complexity increases, so too does the likelihood of a holding multiple medications prescription. 
The MetS group, who evidenced more medical problems, may have a greater demand for regular 
medication adherence, thereby demonstrating a greater degree of coactive autonomic control in 
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response to this perceived demand. Conversely, HC participants who likely had fewer 
medication concerns may not have appraised this segment in the same way, leading to a less 
dramatic autonomic response.  
We also set out to assess whether dominant motivational states (i.e., “challenge” vs. 
“threat”) could be associated with MetS by examining variations in cardiac and vascular 
reactivity to our experimental manipulation. Unfortunately, due to technological limitations of 
the monitoring equipment, we were unable to verify that TPR readings corresponded to the 
distinct start- and end-points of our stressor tasks, and therefore, we could not test whether 
changes in TPR corresponded to experimental manipulation. Instead, we examined whether PEP 
and TPR across the full experimental task (approximately 30 minutes) as an analogue. Initial 
findings suggested that PEP, TPR, and an interaction term representing their combined effect 
was predictive of MetS; however, we were unable to determine that specific indicators were 
statistically associated with our outcome, so these models could not be interpreted. We then 
attempted to compare MetS groups on PEP and TPR at each point of measurement to further 
determine if distinct CV patterns underlying motivational state varied between HC and MetS 
groups. Our primary hypothesis was not supported, however, as we were unable to detect 
differences in PEP or TPR at sequential points of measurement. This null finding is most likely 
due to the temporal staggering in both task engagement and baseline recovery across the sample.  
Our final aim was to examine the influence of cardiac autonomic control on health 
behaviors and treatment adherence among individuals with MetS. We hypothesized that lower 
CAC would predict poorer health behaviors, higher BMI and poorer medication adherence. 
Indeed, the hypothesis gained partial support. Across the whole sample, decreased CAR scores 
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and male gender were associated with an increased likelihood of smoking, while controlling for 
experimental group. This pattern may be representative of attempts to behaviorally regulate 
sympathovagal activity. None of the other models suggested that CAB or CAR were predictive 
of poor treatment adherence. Because these models failed to adequately predict the identified 
outcomes, the indicator variables we measured cannot be used to explain patterns of disease 
progression in MetS. It is possible that with a larger sample, these hypotheses could be addressed 
with greater cogency and more vigorous conclusions may be drawn.  
Limitations 
A primary limitation of the present investigation pertains to experimental power and 
external validity given current sample size. Most notably, statistical control of potentially 
confounding variables becomes problematic in small samples, as inclusion of covariates expends 
degrees of freedom. This concern was particularly relevant as we attempted to account for the 
impact of CV medications on our outcome variables. For more robust hypothesis testing and 
replication of the present findings, collection of data in a larger sample is warranted. Second, we 
observed a number of missing data, primarily within the patients’ laboratory findings maintained 
in their medical record. These particular data could not be imputed because they were not 
missing at random; rather, they were collected (or not collected) based on best practice 
guidelines of clinical care, which are directly related to disease status and progression. Indeed, if 
these data were to be imputed, it would likely lead to biased estimates. Nonetheless, inclusion of 
these observations would have allowed for a number of analyses that were not feasible in the 
present data set (e.g., examination of MetS as a continuous variable thereby permitting 
estimation of illness severity). A third limitation, as noted above, involved technological issues 
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in BP measurement. Obtaining a non-continuous measure was the most logistically appropriate 
option for this investigation but it presented a significant barrier when comparing cardiovascular 
reactivity across experimental groups. Without a continuous measure of BP, and in view of the 
necessarily variable boundaries of the experimental tasks, we could not compare participants’ 
TPR responses during task engagement. This circumstance limited out ability to test differences 
along the domain of TPR reactivity, and by extension, to draw conclusions about how such 
differences may potentiate the relationships described here. Finally, due to time restrictions we 
were unable to collect objective measures of diet. Given the role of diet in MetS, these 
measurements would have offered the opportunity to conduct additional analyses pertaining to 
disease etiology and maintenance, which were not feasible in this study. This limitation is also 
related to the problem of using the health behaviors measures here as an analogue of treatment 
adherence. 
Future Directions 
 The most important extension of this work would be to develop longitudinal, prospective 
studies to examine the extent to which CAC and its constituent indicators may be implicated in 
the etiology of MetS. Within this type of study design, longer periods of monitoring (e.g., over a 
period of hours) across many days, weeks, or months may be helpful to clarify the timeline along 
which etiological mechanisms operate. A particular strength of this kind of study could be 
examination of other stressors types (e.g., medical visits vs. family interactions) to better 
understand the circumstances within which stress is pathogenic. Additionally, our findings are 
consistent with the notion that direct engagement in stress cues is associated with potentially 
maladaptive responses among individuals with metabolic abnormalities. One implication of such 
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findings is that certain patterns of reactivity contributes to disease maintenance, given the 
established influence of stress in MetS; it is therefore possible that prototypical ‘profiles’ can be 
observed among subgroups of individuals with MetS. Cluster or latent class analysis could help 
uncover these subgroups of individuals. Similarly, understanding protective factors in this 
population would offer an important perspective on minimizing the damaging effects of 
dysregulated CAC. Coping may prove to be one such factor that could safeguard against 
progression of MetS. Given the emphasis on behavioral interventions in managing stress, 
examination of coping skills would serve as a crucial component of programmatic research in the 
physiology of illness. Finally, repercussions of autonomic reactivity may be evident in other 
systems, such as immune and endocrine reactivity (e.g., HPA-axis). Given the emerging 
emphasis on inflammation as a cross-cutting feature of a number of diseases, including MetS 
(Lee & Pratley, 2005), it would be valuable also to evaluate the extent to which autonomic 
tendencies identified here contribute to patterns of immune functioning and/or inflammation.  
Conclusions 
As reviewed above, previous findings have supported the notion that psychological 
appraisal in response to external demands are associated with physiological changes that may 
have deleterious effects over time. Such evidence has been used to advance current etiological 
models of MetS (Aubert & Raemaekers, 1999; Bellavere et al., 1992; Krzesinski, Gielerak, & 
Kowal, 2013; Malliani, 2005; McGrady, 2010). The findings of the present study also contribute 
to this existing body of evidence, supporting psychological contributions to physical illness and 
may offer additional information about the conditions under which psychological reactivity is 
involved in disease progression.  
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Though limitations exist, this study has implications both for assessment and treatment 
monitoring, especially given the potential relationship between CAC and health and wellness 
ques presented here. On-going hemodynamic evaluation of individuals with MetS would allow 
application of basic physiological concepts to relevant real-world settings in order to predict 
patient outcomes and response to treatment. Notably, the ambulatory nature of these monitoring 
procedures is consistent with ongoing efforts to enhance mobile health (mHealth) and can even 
inform remote delivery of clinical interventions such as biofeedback. Crucially, our results can 
be applied to preventative efforts to help individuals at risk for metabolic syndrome identify and 
thereby alter responses to stress. 
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Appendix A: Descriptive Statistics for Study Variables by Experimental Group 
 
Healthy Control (N=25) Metabolic Syndrome (N=25) 
 M (SD) Range M (SD) Range 
Baseline PEP 89.36 (22.04) 50.00–126.00 96.16 (25.80) 68.00–142.00 
Baseline RSA 4.75 (1.20) 2.66–7.23 4.97 (1.11) 2.87–7.58 
Baseline CAB -0.24 (1.59) -3.13–2.61 0.24 (1.63) -1.91–3.85 
Baseline CAR 0.05 (1.16) -1.99–2.92 -0.05 (1.24) -3.78– 1.73 
HWI, Medication – – – – 
PEP 88.40 (25.77) 54.00–134.00 91.12 (25.93) 64.00–148.00 
RSA 4.95 (1.20) 2.72–7.59 5.12 (1.43) 2.46–7.74 
CAB -0.12 (1.44) -3.02–2.65 0.12 (1.55) -2.34–3.79 
CAR -0.01 (1.28) -2.94–2.25 0.01 (1.42) -3.92–2.50 
HWI, Diet – – – – 
PEP 87.68 (24.14) 56.00–128.00 88.56 (28.06) 46.00–146.00 
RSA 5.04 (1.27) 2.60–7.74 5.02 (1.36) 2.61–7.10 
CAB -0.01 (1.56) -2.75–2.46 0.01 (1.40) -2.12–2.43 
CAR 0.02 (1.10) -1.78–2.08 -0.02 (1.59) -3.94–2.36 
HWI, Exercise – – – – 
PEP 86.88 (26.36) 50.00–132.00 92.56 (29.12) 62.00–146.00 
RSA 5.15 (1.30) 1.46–7.44 4.73 (1.41) 2.50–7.84 
CAB 0.05 (1.49) -2.54–2.78 -0.05 (1.58) -2.43–2.32 
CAR 0.26 (1.19) -2.56–1.83 -0.26 (1.37) -3.06–2.63 
HWI, Stress – – – – 
PEP 86.72 (24.21) 54.00–132.00 91.44 (28.60) 64.00–142.00 
RSA 5.34 (1.22) 2.79–8.08 4.60 (1.23) 2.59–6.85 
CAB 0.20 (1.48) -2.30–3.07 -0.20 (1.47) -2.57–2.68614 
CAR 0.38 (1.16) -2.14–2.42 -0.39 (1.45) -3.79–1.53452 
HWI, Coping – – – – 
PEP 86.56 (24.92) 52.00–130.00 92.00 (28.36) 64.00–144.00 
RSA 4.85 (1.46) 1.21–7.73 4.84 (1.17) 2.99–7.00 
CAB -0.10 (1.61) -2.81–2.54 0.10 (1.39) -1.99–2.35 
CAR 0.10 (1.28) -2.87–2.08 -0.10 (1.39) -3.25–1.95 
MA, Serial 7s – – – – 
PEP 84.48 (24.58) 54.00–132.00 90.56 (28.63) 64.00–148.00 
RSA 4.72 (1.36) 1.59–7.31 4.34 (1.40) 1.86–6.89 
CAB 0.02 (1.54) -2.29–2.60 -0.02 (1.63) -2.77–2.75 
CAR 0.25 (1.13) -2.15–2.43 -0.25 (1.31) -3.23–2.30 
MA, Multiplication  – – – – 
PEP 84.88 (22.91) 54.00–124.00 91.12 (28.64) 62.00–144.00 
RSA 5.01 (1.22) 2.96–6.86 4.52 (1.56) 1.98–7.88 
CAB 0.05 (1.40) -2.13–2.80 -0.05 (1.55) -2.90–2.78 
CAR 0.29 (1.06) -1.90–2.29 -0.29 (1.59) -3.97–2.75 
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Appendix Table A (continued) 
 
Healthy Control (N=25) Metabolic Syndrome (N=25) 
 M (SD) Range M (SD) Range 
TPR (dyn·s·cm
−5
) – – – – 
300 sec 6.05 (2.39) 2.84–10.07 6.05 (3.23) 2.51–17.06 
600 sec 5.44 (1.87)  2.75–9.65 6.75 (3.99) 3.11–16.81 
900 sec 5.79 (2.71) 2.75–14.42 6.36 (3.35) 2.29–15.64 
1200 sec  5.56 (2.09) 2.13–10.40 5.63 (2.37) 2.38–11.22 
1500 sec 6.17 (2.93) 2.26–12.94 5.98 (3.09) 2.51–14.34 
1800 sec 5.88 (2.18) 2.88–9.67 6.63 (3.41) 2.97–15.03 
PEP (milliseconds) – – – – 
300 sec 86.56 (23.86) 48.00–132.00 90.16 (27.11) 58.00–146.00 
600 sec 90.42 (24.22) 52.00–126.00 94.40 (29.42) 58.00–148.00 
900 sec 82.00 (24.69) 48.00–128.00 98.40 (27.09) 58.00–150.00 
1200 sec 84.64 (22.78) 42.00–134.00 98.40 (28.48) 60.00–152.00 
1500 sec 85.76 (24.30) 50.00–132.00 98.88 (27.56) 58.00–144.00 
1800 sec 87.75 (23.34) 44.00–122.00 95.23 (26.11) 58.00–150.00 
Self-Report Measures – – –  
HADS-A 6.76 (3.42) 1.00–13.00 7.12 (3.74) 2.00–14.00 
HADS-D 3.76 (2.44) 0.00–8.00 5.12 (3.34) 1.00–13.00 
QOL – Physical 15.09 (3.36) 7.43–20.00 13.58 (2.95) 8.57–18.29 
QOL – Psychological 14.96 (2.49) 11.33–19.33 13.70 (3.07) 7.33–17.33 
QOL – Social 14.45 (3.52) 8.00–20.00 12.32 (3.32) 6.67–20.00 
QOL – Environmental 16.21 (2.78) 9.00–20.00 15.88 (2.63) 10.50–20.00 
MMAS 2.36 (1.73) 1.00–7.00 3.16 (2.06) 2.00–8.00 
Note: CAB = PEP = pre-ejection period; RSA = respiratory sinus arrhythmia; Cardiac 
Autonomic Balance; CAR = Cardiac Autonomic Control; HWI – Health and Wellness Interview; 
MA = Mental Arithmetic; TPR = total peripheral resistance; PEP = pre-ejection period; HADS-
A= Hospital Anxiety and Depression – Anxiety Scale Score; HADS-D= Hospital Anxiety and 
Depression – Depression Scale Score; QOL – Physical = WHO Quality of Life–Brief–Physical 
Domain; QOL – Psychological = WHO Quality of Life–Brief–Psychological Domain; QOL – 
Social = WHO Quality of Life–Brief –Social Domain; QOL – Environmental = WHO Quality of 









I am interested in how you perform a couple of metal math calculations. In a moment, I will ask you to 
perform some subtraction problems. When I say to, I want you to subtract 7 from 100 and continue 
subtracting 7 from each subsequent answer. Please continue until I tell you to stop. Do you have any 
questions?” 
 
“Ready? Begin” Begin timing for 1 minute. 
 
Start Time: _____: _____: _____ 
 
End Time: ______: _____: _____ 
 
Correct answers (left to right): 
 
NOTE: For each incorrect answer, instruct the participant: “Incorrect. Please begin again.” 
100 93 86 79 72 65 
58 51 44 37 30 23 
16 9 2 -5 -12 -19 
-26 -33 -40 -47 -54 -61 
-68 -75 -82 -89 -96 -103 
 
 
“Thank you. Next, I would like you to multiply 4 by 3 and continue multiplying each answer by 3 until I 
tell you to stop. Do you have any questions?” 
 
“Ready? Begin” Begin timing for 1 minute. 
 
Start Time: _____: _____: _____ 
 
End Time: ______: _____: _____ 
 
NOTE: For each incorrect answer, instruct the participant: “Incorrect. Please begin again.” 
12 36 108 324 972 2,916 
8,748 26,244 78,732 236,196 708,588 2,125,764 
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APPENDIX C: HEALTH AND WELLNESS INTERVIEW 
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Health and Wellness Interview 
Directions: 
“I am interested in understanding any difficulties you have had with your health and wellness. In particular, I would 
like to know about your experience taking medication, following a healthy diet, being physically active, stress 
patterns and coping.” 
I. Medical Adherence    Start Time: ______: _____: _____   End Time: ______: _____: _____  
“Are you taking your prescription medication regularly?” ☐ Yes ☐ No 
“What barriers do you perceive to taking your medication?” 
☐ Inconvenient ☐ Cost ☐ Side Effects ☐ Not Important ☐ Not Motivated ☐ Forget 
Other/Notes:             
II. Nutrition    Start Time: ______: _____: _____   End Time: ______: _____: _____  
“Are you following a healthy diet?”  ☐ Yes ☐ No 
 “What barriers do you perceive to following a healthy diet?” 
☐ Inconvenient ☐ Cost ☐ Time/Energy ☐ Not Important ☐ Not Motivated ☐ Forget 
Other/Notes:             
III. Exercise    Start Time: ______: _____: _____ End Time: ______: _____: _____  
“Are you getting regular exercise?”  ☐ Yes ☐ No 
“What barriers do you perceive to getting regular exercise?” 
☐ Inconvenient ☐ Pain ☐ Time/Energy ☐ Not Important ☐ Not Motivated ☐ Forget 
Other/Notes:             
IV. Stress    Start Time: ______: _____: _____  End Time: ______: _____: _____ 
“Are you feeling stress from everyday hassles?”  ☐ Yes ☐ No 
“What areas in particular do you find most stressful” 
☐ Finances ☐ Employment ☐ Home Life ☐ Health ☐ Relationships ☐ Housing ☐ School 
Other/Notes:             
 “On a scale of 0 to 10, with 10 being the most stress, how much stress do you feel on a daily basis? 
0 1 2 3 4 5 6 7 8 9 10 
V. Coping             Start Time: ______: _____: _____  End Time: ______: _____: _____  
“Are you managing your stress very well?”  ☐ Yes ☐ No 
“What barriers do you perceive to managing your stress?” 
☐ Knowledge ☐ Ability ☐ Relationships ☐ Responsibilities ☐ Not Motivated ☐ Unimportant 
Other/Notes:                      
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